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THE ORIGIN OF MULTIPLE SCLEROSIS REVISITED: THE CASE FOR A
SOLUBLE TOXIN

Kareem Rashid Rumah, Ph.D.
The Rockefeller University 2014

After nearly two hundred years of scientific inquiry, the cause of Multiple
Sclerosis (MS) remains unknown. Although generally considered an
autoimmune disease, recent pathological findings have challenged the longstanding autoimmune view of MS. Indeed, lesions that are just hours past their
initial onset display evidence of cellular degeneration in the absence of an
inflammatory infiltrate. This seminal finding begs the fundamental question, if
immune cells do not participate in early tissue damage in MS, what is the
mysterious triggering agent?
In the first half of this thesis, I will propose that a soluble bacterial toxin,
Clostridium perfringens epsilon toxin (ETX), may be the long sought
environmental trigger for MS. ETX is a neurotoxin with a unique tropism for the
brain tissues that are specifically damaged during acute MS exacerbations, the
blood-brain barrier and the myelin sheath. Using a Western blot seroreactivity
assay, I have identified a 10-fold increase in anti-ETX seroreactivity when
comparing MS patient samples to that of controls. Furthermore, PCR analysis of
bacterial cultures from patient stool samples has yielded the discovery of the first
human known to harbor C. perfringens type B, an ETX secreting bacterium that is
not part of the normal human microbiota. Intriguingly, this individual was
found to be in the early stages of developing MS. I have also determined that MS
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patients are 2X less likely to harbor the human commensal C. perfringens type A,
which has been shown to outcompete toxin-producing C. perfringens strains, e.g.
type B, within a shared ecological niche. Therefore, commensal type A may
protect against type B dysbiosis and may protect against developing MS.
Although the ETX/MS hypothesis is obscure at best, ETX’s extreme
potency has driven interest in identifying its cellular receptor. Indeed, ETX is the
third most potent toxin known to man, following only Clostridium botulinum and
tetanus toxins in lethality. For this reason, it is considered a legitimate
bioterrorism threat. Despite decades of research, the ETX receptor is still yet to
be identified.
In the second half of this thesis, I will propose that the tetraspan
proteolipid, Myelin and Lymphocyte protein (MAL) is a bona fide ETX receptor.
Recombinant expression of MAL by an ETX resistant Chinese Hamster Ovary
(CHO) cell line confers both ETX binding and susceptibility. Additionally,
probing tissues harvested from MAL knockout (KO) mice with fluorescently
labeled ETX demonstrates a complete abolishment of ETX binding. Finally, MAL
KO mice display a remarkable level of ETX resistance even when exposed to
1000X of our experimentally determined LD50 for wild type animals. Taken
together, these data suggest that MAL is both necessary and sufficient for ETX
binding and toxicity.
In summary, I have generated data suggesting that an increased exposure
to C. perfringens epsilon toxin may exist in the MS population when compared to
controls. This may be important, as ETX specifically targets the blood-brain
barrier and the myelin sheath, both of which degenerate during acute MS
exacerbations. To my knowledge, ETX is unlike any other candidate MS trigger,
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as it provides a clear mechanism for how blood-brain barrier disruption and
demyelination may occur during an MS relapse. I have also identified Myelin
and Lymphocyte protein, as a functional ETX receptor. Identifying the
mechanism by which ETX targets cells may help counteract its use as a biological
weapon. Furthermore, this discovery may open new avenues for translational
research, e.g. novel methods for targeting and bypassing the blood-brain barrier;
a major hurdle to drug delivery in the central nervous system.
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I dedicate this thesis to two incredibly influential people in my life, my late
grandmother, Lorine Pitt and the late Dr. Timothy Murrell. I cannot express in words
the gratitude that I have for my grandmother’s presence in my life, but I can honestly say
that without her love and constant encouragement I would not be on the path that I am
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CHAPTER 1
The Current View of Multiple Sclerosis

Multiple Sclerosis (MS) is a neurological disease that cripples its victims.
Although rarely fatal, it significantly diminishes quality of life. MS is considered
a disease of young adults, as the diagnosis is usually made between the ages of
20 and 40. Due to the youth of its target population, MS affects not only the
patient, but also the family and the community, as it impairs the productivity of
young people in their prime.
One in 500 individuals of European ancestry living in temperate climates
suffer from MS (Haines 2004). Additionally, women are 2.3x more likely to
acquire the disease than men (Alonso and Hernan 2008). However, African
Americans and other minorities are also affected, often suffering from a more
aggressive disease course (Cree, Khan et al. 2004).
Interestingly, Multiple Sclerosis comes in two different forms; a Relapsing
Remitting form (RRMS), characterized by relative periods of health that are
abruptly interrupted by acute episodes of symptomatic exacerbations, and a
Primary Progressive form (PPMS), in which the patient suffers from a steady
decline of neurologic function. It is important to note that RRMS comprises close
to 90% while PPMS comprises about 10% of MS cases (Miller and Leary 2007).
Because of this distribution, RRMS will be the main focus of this thesis.
Common MS symptoms include disturbances in vision, balance, motor,
sensory, autonomic and cognitive function. Despite the initial waxing and
waning pattern of RRMS, many patients will later make the transition to a
1

secondary progressive phase (Tremlett, Yousefi et al. 2009), leading to a steady
decline in neurological function and ultimately resulting in severe disability.
Acute MS lesions are characterized by focal breakdown of the
neuroprotective blood-brain barrier (BBB) and by the loss of oligodendrocytes
and CNS myelin, the fatty insulation of CNS axons, which facilitates saltatory
conduction (Arroyo 2000). Additionally, the typical MS lesion is sharply
circumscribed with a well-defined lesion edge. It is also important to note that
axons are relatively spared in active MS lesions (Prineas and Parratt 2012).

The BBB defined: The BBB is a protective barrier formed by the blood vessels of
the brain. The capillary network of the central nervous system forms a barrier
that limits the flow of solutes from the blood to the brain.

This barrier is

extremely important for maintenance of brain homeostasis and suitable ionic
concentrations for controlled neuronal excitability. In addition to preventing the
entry of many systemic toxins from entering brain tissue, the BBB also reduces
the frequency of brain immune surveillance when compared to other organs.
To perform such specialized functions, brain endothelial cells (ECs),
which form the lumen of blood capillaries, possess many unique properties
when compared to endothelial cells in the periphery.

CNS ECs form high

electrical resistance tight junctions between their adjoining cell walls (Rubin and
Staddon 1999). Tight junctions prevent virtually all molecules from entering the
brain by forming tight seals between adjacent EC membranes, creating fence like
structures. This adaptation prevents much of the paracellular transport that
occurs in other organs. CNS ECs also display lower rates of transcytosis and lack
the fenestrations observed in peripheral ECs (Kaya, Chang et al. 1996),
2

adaptations that limit the transcellular transport of fluid phase molecules.
Fenestrated vessels are no more permeable to plasma proteins than are BBB
vessels, but such vessels are much more permeable to water, ions, and small
solute molecules (Kaya, Chang et al. 1996). Meanwhile, lipophilic molecules of
low molecular weight can enter the brain through passive diffusion. However,
the brain possesses transporters such as P-glycoprotein, which generally
transports these lipophilic molecules back into the blood (Rubin and Staddon
1999). While these features have evolved to maintain a stable CNS environment
and restrict the entry of toxins, active transporters present on the surface of
endothelial cells supply the brain with specific nutrients and survival factors.

Figure 1. An Illustration of the Blood-Brain Barrier. Schematic comparison
between brain (left) and peripheral (right) capillaries. (Misra, Ganesh et al. 2003)

3

rapid nerve conduction. A new study genetically uncouples the myelin-producing function of the myelinating cells from th
in axonal survival, suggesting that neurodegenerative disorders characterized by axonal loss might result from defects
myelinating cells whether myelin irregularities are apparent or not.

CNS myelin defined: CNS myelin is a multilamellar spiral of specialized
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A simplified view of the autoimmune MS hypothesis: In addition to BBB
damage and loss of CNS myelin, termed demyelination, it has been noted that
acute MS lesions display a heavy accumulation of immune infiltrates such as
activated T cells, B cells and phagocytic macrophages. While it is generally
accepted that the histopathological hallmark originates from a breach in the
integrity of the BBB, how this initial event occurs remains unknown. As
illustrated below in Figure 3, it is suspected that an unknown trigger causes
upregulation of adhesion molecules on the endothelium of the brain, optic
nerves and spinal cord, allowing leukocytes to home to and traverse vessel walls
to enter the normally immunologically privileged central nervous system. If
lymphocytes programmed to recognize myelin antigen exist within the cell
infiltrate, they may trigger autoimmune demyelination and result in MS.
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Early Descriptions of MS

In the 1824 publication Maladies de la moelle epiniere, Charles Prosper
Ollivier D’Angers provided the first description of Multiple Sclerosis. In 1808, he
encountered a 20-year-old man who developed transient weakness of his right
foot. At the age of 17, the young man recalled a period of feeling tired and
languid. By 29 years of age, he had weakness of both legs. By age 30, he noted
that the hot waters of a spa induced loss of feeling in his right leg and numbness
and clumsiness of his hands; an early description of the “hot bath test.” He
suffered from urinary retention, and a progressive deterioration in his motor
function, speech and ability to write. The young man felt cold water as hot and
he felt “galvanic shocks” when his paretic right hand touched his thigh. He
seemed intellectually intact and retained the “gaiety of his character” despite his
advanced disability. Ollivier D’Angers suspected the cause to be a “myelitis”
due to an infection, and suggested a treatment regimen of bleeding and blood
leeching (Murray 2005).
Robert Carswell, a British pathologist, provided the first pathological
description/drawings of MS in an atlas of pathological conditions published in
1838 (Carswell 1838). He noted a brown discoloration of the spinal cord (Figure
4) and postulated that the lesions were caused by a deficiency of blood supply to
the affected regions. Meanwhile, Jean Cruveillhier, a French contemporary,
contributed similar drawings published sometime after 1841. He was the first to
recognize the essential feature that islands of “grey degeneration” were replacing
the white matter. Cruveillhier, felt that this condition was caused by a general
suppression of sweat (Murray 2005).
7

Figure 4. An Early Drawing of MS Lesions. An illustration by Robert Carswell
depicting brown discoloration of the normally white spinal cord. (The Multiple
Sclerosis Society of Ireland)
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Despite the prior contributions mentioned above, Jean-Martin Charcot is
credited with the “discovery” of MS. In his 1868 lectures, Charcot distinguished
MS as a unique disease state and clearly defined its specific symptomatology. He
outlined the clinical appearance of intention tremor, nystagmus, and scanning
speech as three reliable indicators of an MS diagnosis, which would later be
called the Charcot triad. Charcot not only provided the first clear delineation of
MS symptoms, but also conducted his own pathological investigation. Like
Carswell and Cruveillhier, he drew many illustrations of gross anatomical
lesions. In addition, he produced renderings of the microscopic changes. Using
a carmine stain, Charcot noted the common presence of a central capillary, with
surrounding demyelinated axons. He noted that although the axons were
relatively spared, there was axonal thinning. Charcot also depicted “voluminous
fatty globules,” the result of myelin breakdown, and eventual removal of the
fatty myelin sheath (Murray 2005). But most important for Charcot was the
proliferation of astroglia and their reticulated fibers (the glial scar). He felt that
MS was primarily a disease of glial overgrowth with secondary changes in the
blood vessels (Compston 2005). Charcot writes:
Undoubtedly, the multiplication of nuclei and the concomitant
hyperplasia of the reticulated fibers of the neuroglia constitutes the initial,
fundamental fact, and necessary antecedent; the degenerative atrophy of
the nerve elements, is consecutive and secondary; it had already begun
when the neuroglia gave way to the fibrillary tissue through the wasting,
afterwards, proceeded with greater rapidity. The hyperplasia of the
vascular parieties plays merely an accessory part.
Not until the early 1900’s did improvement on these early works appear.
In 1916, the Scottish pathologist James Walker Dawson published his seminal
thesis work The Histology of Disseminated Sclerosis, which is widely recognized to
be the first systematic study to significantly advance beyond Charcot’s
9

observations. It is perhaps the most important contribution to British neurology
in that generation (McAlpine 1946).
Dawson studied nine MS cases, and provided many key pathological
insights. He observed the following key features:
•

MS plaques are deposited in relation to the distribution of the veins and to the
walls of the ventricles.

•

Both grey and white matter may be affected, however, lesions more often affect the
white matter.

•

Older patches are firmer than the normal brain substance (sclerotic), but fresh
patches are softer (malacotic) than the normal brain.

•

A striking microscopic feature of lesions is the sharp demarcation of the lesion
edge.

•

An inflamed blood vessel is often present in the center of a lesion.

After his detailed investigation into the pathologic features of MS, Dawson
contemplated the theories of the day regarding a triggering agent. In his thesis,
he quotes Byrom Bramwell’s theory that “the sclerotic lesions are the result of
some irritant which is distributed through the nerve centres by the bloodvessels”(Dawson 1916). Dawson juxtaposes the exogenous irritant theory with
the idea championed by Strumpell and Mueller that MS is triggered by an
endogenous factor. Dawson summarizes the endogenous theory as he writes,
“the disease is due to some developmental or congenital defect of the neuroglial
or nervous tissue (perhaps similar to, or analogous to, the gliomatosis in cases of
syringomyelia), which renders it more vulnerable or liable to be affected by
irritation than the neuroglial or nervous tissue of the normal individual”
(Dawson 1916). Charcot also favored the endogenous hypothesis, as he believed
that MS was a consequence of astroglial overgrowth.
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Although initially unimpressed with the exogenous toxin theory, feeling that
the effects of a toxin would be diffuse rather than focal, Dawson later changed
his mind and concluded the following:
•

Multiple Sclerosis is likely due to a specific external agent.

•

The external agent is likely a soluble toxin.

•

Somehow the agent enters only certain areas due to some local vascular change.

It should be noted that in the present day study of MS, Dawson’s name
continues to be linked with the flame-like plaques radiating off the corpus
callosum on sagittal sections of the brain on MRI that are pathognomonic for a
diagnosis of MS, called Dawson’s fingers.

Figure 5. An MRI Image of Dawson’s Fingers. A sagittal MRI of an MS patient
with flame-like lesions radiating off the corpus callosum (Dawson’s fingers).
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What Causes MS? Current Ideas
The theories about what causes MS changed as the major advances in
medical science changed. In the era of Pasteur and Koch, it seemed to be
an infectious disease; in the era of environmental illnesses, it seemed a
disease due to some toxin; when epidemiological techniques improved,
interest centered on mysterious demographic and environmental factors;
as immunology flourished, it became an immunological disease, and in
this age of genetics, gene probes, and the human genome, there’s great
interest in a genetic factor. With advances in virology, slow virus
infections, and now prions, it is again being considered an infectious
disease, with the virus perhaps acting as a trigger in a genetically
predisposed individual. One might ask if the theories of MS just follow
the current interest in science, but it is evident that each stage provided
important building blocks for the next. (T. Jock Murray 2005)
The cause of MS has eluded researchers for centuries. The longevity of
this mystery has led to scientific inquiry encompassing almost every biological
discipline imaginable; bacteriology, virology, immunology, genetics,
epidemiology, endocrinology and the list continues. Perhaps the most
appropriate place to start when summarizing the many theories proposed for the
elusive MS trigger would be investigations into the epidemiology of the disease.

Genes and MS
Familial studies have contributed greatly to our current understanding of
the genetic factors involved in MS. Sadovnick et al. performed a comprehensive
study of the risk of developing MS if a relative had a confirmed MS diagnosis
(the proband). As depicted in the table below, there is a marked difference
between the relative risk for a monozygotic twin (RR=190), who shares 100% of
the proband’s genetic material, as compared to an adopted sibling (RR=1), who is
completely unrelated. While this clearly shows that genes matter in MS, the fact
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that there is only a 38% chance of a healthy monozygotic twin later developing
MS suggests that an environmental trigger likely exists.

Table 1. Comparison of Age-Adjusted Risks By Relationship to The Proband.
Data
for aet Northern
European population living in a temperate climate
Sadovnick
al.
(Sadovnick,
Dircks et al. 1999).
Table 1. Comparison of age-adjusted lifetime risks by relationship to the proband – data for a Northern European population living in a temperate climate
Relationship to proband

Approximate risk (%)

Relative risk to general population

% Genetic sharing with the proband

General population
First-degree relative
Dizygotic twin
Monozygotic twin
‘Adopted’ first-degree relative
Half-sib
Offspring of conjugal MSa

0.2
3–5
3–5
38
0.2
1.3
29.5

1
15–25
15–25
190
1
6.5
147.5

0
50
50
100
0
25
50b

a

It may be more appropriate to compare crude rates for this group (18).
The child shares 50% of the genetic material with the affected mother and 50% of the genetic material with the affected father.
c
Unpublished data from the CCPGSMS.
b

Overall risks: children and sibs of probands

impossible to determine, given available data at this
time,techniques,
whether it is more
accurate to cite ‘crude’ or
Withthroughout
the advancement
of genetic
probing
MS investigators
Note that,
this paper,
the term
‘age-adjusted’ risks for the special case of offspring
‘proband’ will refer to the first ‘affected’ individual
of conjugal MS matings.
have
morecomes
and more
geneticThe
loci that
seem to be associated with MS.
in theidentified
pedigree who
to attention.
proband is not necessarily the consultand.
MS risks in ‘multiplex families’ and ‘bilineal families’
Lifetime
risks genetic
for children
and sibs, controlling
The
strongest
association
was identified
relatively early in the modern
for the amount of genetic sharing, are given in Table
At present, specific accurate risk data are not avail1. Depending
on theInamount
of genetic
sharing,
ableSNP
whenanalysis
the pedigree
indicatesa either
era
of genetics.
the early
1970’s,
highthe
density
revealed
strongi) bilineal
relative risk to family members compared with that
MS or ii) ‘loaded’ multiplex families.
for the general population can range from 1
association
with the HLA-DRB1* 1501 haplotype. The International Multiple
(adopted sibs and children of the MS proband, with
Bilineal MS. As MS is a relatively common disorwhom they share no genetic material) to 190
der among Caucasians of Northern and Central
Sclerosis
Genetics
has
determined
the odds ratio for HLA-DRB1*
(monozygotic
co-twinsConsortium
of MS probands,
with
whom
European ancestry (5), asymptomatic individuals
they share 100% of their genetic material).

1501 to be 5.8; 95% CI, 3.53 to 9.53 (p= 1.83×10−17) (Hafler, Compston et al. 2007).
Risks to sibs of probands: age of onset and parental MS

The
statusHuman
known Leukocyte Antigen (HLA) system is the name given to major
When counselling full complex
sibs of MS(MHC)
probands,
histocompatibility
in risks
humans. The MHC’s function is to present
can be refined from those given in Table 1, when
information is available on the age of onset in the
both
self and foreign antigens to T lymphocytes. HLA-DRB1* 1501 is part of the
proband and whether or not one parent has MS
[(17); see Table 2]. Research is underway as part of
MHC
class II to
system
that
found
on the surface of professional antigen
the CCPGSMS
determine
theis
effect
of co-variates
on risks for other categories of relatives, such as
presenting
cells (dendritic cells, macrophages and B cells). Antigens that exist
children of probands.

outside of the antigen-presenting cell are phagocytosed, degraded and loaded
Risks to offspring of conjugal matings

The special circumstance of determining the risk to
offspring of conjugal matings (both parents have
MS) is only recently being addressed using a popu13
lation-based approach rather than anecdotal case
reports (21). The results of one published study (18)
and unpublished data from the CCPGSMS support

onto the MHC II molecule as a short polypeptide for presentation to CD4+ helper
T cells. Additionally, intracellular (self) antigens can also be presented via MHC
II following autophagy (Blum, Wearsch et al. 2013).

Figure 6. A Schematic of MHC Class II Antigen Processing (Blum, Wearsch et
al. 2013)
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On face value, HLA-DRB1* 1501’s association with MS seems to support
an autoimmune view of MS, as this haplotype is also associated with stereotyped
autoimmune diseases such as Goodpasture syndrome (Phelps and Rees 1999),
Systemic Lupus Erythematosus (SLE) (Takeuchi, Nakano et al. 2005) and
Sjogren’s syndrome (Manoussakis, Georgopoulou et al. 2004) for which
autoantigens are known. However, it should also be noted that the HLA-DRB1*
1501 haplotype is also associated with diseases of clear infectious origin; cervical
cancer (human papilloma virus) (Apple, Erlich et al. 1994). Additionally,
infectious triggers for autoimmune disease such SLE are still popular areas of
investigation. Therefore, distinguishing a disease as autoimmune or infectious in
nature is often times not clear-cut. Finally, although there is a concentration of
the HLA-DRB1 *1501 haplotype in the MS patient population, it is not present in
all MS patients. Additionally, not all people who carry HLA-DRB1 *1501 have
MS; thus HLA DR haplotypes are not necessary or sufficient to produce the
disease.
Other strongly associated loci are Interleukin 2 receptor-alpha (IL2RA); 2
synonymous SNPs in intron 1, and Interleukin 7 receptor-alpha (IL7RA); 1 nonsynonymous SNP in exon 6 (Hafler, Compston et al. 2007). Functionally, the
non-synonymous SNP in exon 6 of IL7RA would lead to a decrease in IL7/IL7RA
signaling. The mutation is found in a transmembrane domain and causes
increased skipping of the exon, increased production of soluble IL7RA and
decreased expression of membrane-bound IL7RA (Online Mendelian Inheritance
in Man). The contribution of this SNP appears to be modest, however, with an
odds ratio of 1.18; 95% CI 1.11 to1.26 (p = 2.94×10−7)(Hafler, Compston et al.
2007).
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In summary, while we can identify that genes are associated with MS, it is
clear that genes are not enough to trigger the disease. It is striking that many of
the MS associated loci are involved in immune function, and it is tempting to
assume that because of this, MS must be autoimmune in nature. However, it is
important to consider that the immune system evolved primarily to fight
invading pathogens, such that these MS associated loci may just as likely be
involved in host-pathogen interactions as they may be in an autoimmune
process.

The Geography of MS
The incidence and prevalence of MS seem to increase with latitude. MS is
rare in equatorial regions (< 5 per 100, 000) and common in temperate regions

Review

Environment and MS

(>30 per 100, 000) (Marrie 2004).

>80
30–80
<30
No data

Worldwide prevalence of multiple sclerosis per 100 000 population.

Descriptive epidemiology
The geographic and temporal variations in the incidence and

Repetition of prevalence surveys in previously studied
areas suggests that this characterisation of the distribution of
differences in prevalence
between regions may be accounted for by differences in
methods and diagnostic criteria used.20 Zivadinov and
colleagues21 reported an analysis of population-based
16
incidence and prevalence studies of MS from 1980 to 1998.
On the basis of mean crude prevalence rates, they found a
latitude gradient that increased from south to north. The
magnitude of the gradient decreased when these rates were
standardised by age or sex to a common population. The

Figure
7. The
Global
Distribution
ofit MS
2004)Some
prevalence
of MS have
been intensively
studied. However,
risk (Marrie
may be exaggerated.
is important to note that several difficulties may arise when
comparing incidence and prevalence studies from different
areas or time intervals: (1) the populations studied may vary
with respect to their size, age distribution, and ethnicity; (2)
there may be differences between studies in the
completeness of case ascertainment (affected by access to
medical care, availability of diagnostic procedures such as
MRI, public awareness of MS, number of neurologists,

The exact reason for this pattern of global distribution remains unknown,
but a few explanations have been offered. 1) The global distribution mirrors the
concentration of Northern European settlements; people of this racial
background being more at risk for developing MS (Bulman 1992).
2) The distribution may reflect the prevalence of a particular pathogen that
triggers MS (Kurtzke 1993). 3) Decreased vitamin D due to reduced sunlight
exposure in temperate regions may influence MS susceptibility (Ramagopalan,
Dobson et al. 2010). 4) Increased hygiene in developed countries (temperate
zones) may alter host-pathogen interactions and may cause an increased risk of
developing MS (Ascherio and Munger 2007). However, it should be noted that
the latitude gradient is weakening (Ascherio and Munger 2007). Each of these
hypotheses is explored in further detail below.

1) Latitude, Northern European Settlements and MS
Upon closer inspection of the global distribution map, it is striking that
the latitude gradient applies to the Western Hemisphere, and Western Europe,
but it breaks down as one approaches Asia. The simplest explanation for this
phenomenon would be the difference in racial backgrounds in these regions. It
is possible that a European background and a latitude-based modifying factor act
synergistically to trigger MS. To determine if this is the case, we must observe
regions that are genetically homogenous, but differ significantly in latitude.
Unfortunately, there are regions of relatively homogenous populations that obey
the latitude rule e.g. (Australia/Tasmania/New Zealand and the U.K) and
regions that fail to obey this rule e.g. (Norway and Italy/Sardinia) (Rosati 2001).
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Therefore, it is difficult to identify an unequivocal role for latitude in modulating
the risk of developing MS, even when genetic background is controlled.

2) Latitude and a triggering pathogen
John F. Kurtzke has proposed that a pathogen responsible for triggering
MS may have arisen in Southern Norway and spread from this focus throughout
Europe and to North America thus explaining the latitude gradient (Kurtzke
1974). It is conceivable that European settlers may have transported such a
pathogen to the Southern Hemisphere (Australia, Tasmania and New Zealand).
This dependence on European settlements for the spread of said pathogen makes
it difficult to distinguish the existence of bona fide MS pathogen from
confounding variables such as a purely genetic MS risk or shared cultural
practices that may lead to some other environmental exposure.

3) Latitude and Vitamin D Deficiency
The influence of vitamin D on MS susceptibility is currently the
subject of intense investigation. In humans, the main source of vitamin D comes
from the conversion of 7-dehydrocholesterol in skin to active vitamin D3 by an
ultraviolet B (UVB) dependent process. This UVB light comes from sunlight
exposure and since this is reduced with increasing latitude, investigators have
postulated that vitamin D deficiency may play a role in triggering MS (BerlangaTaylor, Disanto et al. 2011). Furthermore, there are reports that MS patients are
often vitamin D deficient (Faridar, Eskandari et al. 2012). George Ebers et al.
have proposed a mechanism for how vitamin D may be involved in MS. Active
vitamin D binds to its nuclear receptor and acts as a transcription factor via the
18

vitamin D responsive element. This molecular complex modulates the
expression HLA-DRB1* 15, an MHC II molecule, which has shown a strong
association with developing MS. Paradoxically, vitamin D seems to increase the
expression of HLA-DRB1* 15. It should also be noted that vitamin D has been
found to modulate up to 5% of gene expression in treated cells, so HLA- DRB1*
15 cannot be considered an exclusive vitamin D target (Berlanga-Taylor, Disanto
et al. 2011). Despite this paradoxical vitamin D mediated increase in HLA-DRB1*
15 expression, we must also consider that vitamin D has been shown to be
protective in experimental autoimmune encephalomyelitis (EAE), the current
Handunnetthi et al.
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animal model for MS (Ascherio and Munger 2007).

Figure 5. A conserved VDRE confers responsiveness to vitamin D to HLA-DRB1
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at the HLA-DRB1
Figure
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vitamin D responsiveness through binding of VDR/RXR.
conserved VDRE confers responsiveness to vitamin D to HLA-DRB1.

(Handunnetthi, Ramagopalan et al. 2010)
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4) Increased hygiene in developed countries of temperate zones
The hygiene hypothesis suggests that increased sanitation causes a delay
in the timing of common childhood infections. This delay causes a shift from
early childhood infections, when the disease process may be benign, to infections
that arise during adolescence or young adulthood. At this later exposure, the
disease may manifest itself in a more malignant form e.g. polio and potentially
MS (Ascherio and Munger 2007). Poorer sanitation in the developing world, i.e.
the tropics, may be protective against developing MS by exposing the population
to the triggering pathogen earlier in life.

Migration and MS
Migration studies have given risen to some provocative concepts in MS.
Despite their many caveats, MS migration studies have consistently shown that
one can reduce risk by moving from a high-risk region to a low-risk region.
However, the reverse statement is not true. Moving from a low-risk region to a
high-risk region does not increase one’s risk, providing that the migration is
made after the age of 15. This suggests that there is a critical period during the
first two decades of life when one acquires a protective factor(s), which remains
stable throughout one’s lifetime (Marrie 2004).

MS Clusters and Outbreaks
MS outbreaks provide a valuable opportunity to potentially identify a
triggering agent. There have been multiple reports of unusually high MS
incidences and identifying a common theme between these clusters may be the
key to identifying said trigger.
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MS outbreak in swayback researchers: In 1947, four of seven researchers
developed signs and symptoms of MS. They were studying swayback, which is
neurological disease of lambs caused by copper deficiency. Another researcher
joined the group later in the study, making a final group of eight men. The
chance of four or more out of eight men developing MS is about one in a billion.
Of interest, MS has not occurred in workers studying swayback disease
elsewhere (Dean, McDougall et al. 1985).

MS outbreak in Key West: In 1984, Dr. William Sheremata, a neurologist from
The University of Miami drew attention to the paradoxically high incidence of
MS in Key West, the southern most tip of the United States of America. He
determined that of the 26, 000 Key West residents, 37 of them had MS (140 per
100, 000), which does not fit the expected low prevalence rate for its respective
latitude. Dr. Sheremata speculated that the exposure may be related to the fact
that Key West did not have an adequate sewage treatment plant and often
endured exposure to unpotable water because of sewage contamination
(Sheremata, Poskanzer et al. 1985). Interestingly, nine of the 37 patients were
nurses, who had at some time in their careers worked in the same community
hospital.

MS outbreak in Mansfield, MA: Fourteen MS cases were identified in the small
town of Mansfield, Massachusetts (population 10, 000). Remarkably, eight of
these patients all lived within the same block between 1932 and 1936. All eight
of these patients lived on the town’s water supply, which was heavily
contaminated at the time. In August 1932, the Department of Public Health
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urged Mansfield to consider a sewerage system and disposal plan to eradicate
excessive sewage bacteria found in all waterways in the center of the community.
A pond located in the thickly settled area of town where the patients lived was
highly contaminated. Eastman writes, “One can only assume that multiple
episodes of exposure to a common contaminated water supply occurred during
the four-year period.” (Eastman, Sheridan et al. 1973)

Multiple Sclerosis outbreak on the Faroe Islands: This outbreak, identified by
John F. Kurtzke, is perhaps the most well known and the most carefully
investigated. The Faroe Islands are a group of 18 Danish islands in the North
Atlantic Ocean situated between Norway and Iceland. According to Kurtzke,
there were no native Faroese suffering from MS in the 20th century before July
1943, when the first of 21 cases occurred. From April 1940 until September 1945,
British troops occupied the Faroe Islands during World War II. Because the
presence of British forces coincided with the MS cases not only in time, but also
in space, Kurtzke postulated that they brought to the Faroes an infectious agent
responsible for triggering MS. Kurtzke goes on to identify a coincident increase
in acute gastrointestinal diseases during the British occupation and proposes that
the MS agent may be an enteric pathogen spread by fecal-oral transmission
(Wallin, Heltberg et al. 2009).

Infections Implicated in MS
Pierre Marie (1853-1940) was the first to champion the idea that an
infection causes MS. He firmly believed that one day “the vaccine of Pasteur or
lymph of Koch” would be sufficient to eradicate the disease (Murray 2005).
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Despite Marie’s optimism, we still struggle with MS in 21st century due to the
fact that such an infection is yet to be identified. Many infections have been
proposed, but viruses have received the most attention. This is partly because
demyelination is a prominent feature in brain lesions caused by known human
viruses e.g. measles virus, which causes SSPE, and JC virus, which causes PML
(Lipton, Liang et al. 2007). Furthermore, viruses can cause demyelinating lesions
in other species, as shown below in Table 2.

Table 2. Experimental Animal Models of Chronic Virus Induced
Demyelination. (Lipton, Liang et al. 2007)
Table 2. Experimental Animal Models of Chronic Virus-Induced Demyelination
Virus

RNA Family

Host

Viral Persistencea/Reservoirb

Canine distemper virus83,84

Paramyxovirus

Dog

!/astrocyte

Mouse hepatitis virus85,86

Coronavirus

Mouse

!/astrocyte

Theiler’s virus87,88

Picornavirus

Mouse

!!!/macrophage

Retrovirus

Icelandic sheep

!!/monocyte/macrophage

89,90

Visna virus
a

Comparative level of persistence: ! " viral antigen only; !! " viral antigen ! limited cell-associated infectious virus; !!! " viral
antigen ! infectious virus.

b

Principal cell harboring virus during persistent infection.
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HHV-4: Epstein-Barr virus, EBV, mainly infects B-lymphocytes and can establish
latency. Exposure to this virus in early childhood is usually asymptomatic, but
infection in adolescence or young adulthood can lead to Infectious
Mononucleosis (IM). Seroreactivity against EBV antigens is found in 99% of MS
patients when compared to 89-95% in controls. In addition, IM occurs in the
same geographic regions as MS (more common farther away from the equator)
and Operskalski et al. found that IM was strongly associated with eventually
developing MS (Operskalski, Visscher et al. 1989). For these reasons EBV has
been the favored MS associated virus (Tselis 2011).

HHV-6: This lymphotrophic virus exhibits a tropism for CD4+ T cells but has a
tendency to infect neural cells. HHV-6 DNA has been detected in brain tissue,
CSF and PBMCs from some MS patients (Challoner, Smith et al. 1995; Kim, Lee et
al. 2000; Alvarez-Lafuente, Garcia-Montojo et al. 2008). Furthermore, a
mechanism of molecular mimicry has been proposed based on the virally
encoded U24 protein’s amino acid homology with myelin basic protein (MBP)
(Tejada-Simon, Zang et al. 2003). Despite these positive findings, an association
with MS remains tenuous due to studies with contradictory results (Martin,
Enbom et al. 1997; Mirandola, Stefan et al. 1999).

Other infections have also been implicated in MS; canine-distemper virus
(Rohowsky-Kochan, Dowling et al. 1995), human endogenous retroviruses
(Nexo, Christensen et al. 2011) and most recently a bacterium, Chlamydia
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pneumonia (Sriram, Stratton et al. 1999). However none of these studies have
yielded conclusive results.

The Immunological Hypothesis
The production of clonally restricted antibodies in the CSF, which are
absent in the serum (oligoclonal bands)(Davenport and Keren 1988), a presence
of immune cells in MS plaques (Lassmann 2011) and changes in the number of
helper and suppressor cells in peripheral blood depending on disease activity
(Waksman 1981) have prompted investigation into a possible immune
abnormality that may be responsible for triggering MS. Similarities between MS
and an immunization-mediated encephalomyelitis (EAE) have also contributed
to the immunological hypothesis.
Although provocative and the prevailing present day hypothesis, the
immunological theory has some striking inconsistencies. To elucidate these
inconsistencies, we must first review the current immunological theory of MS.

Cellular autoimmunity: Thomas Rivers and Francis Schwentker of The
Rockefeller University developed EAE in 1935 (Rivers and Schwentker 1935). In
their initial experiments, they intramuscularly injected eight monkeys with
heterologous brain tissue from rabbits and observed myelin destruction in 7/8
injected animals. Affected animals suffered from ptosis of the eyelids, mask-like
expression of the face, facial paralysis, abnormal position of the head (held to the
right or to the left), blindness and ataxia. Little or no paralysis of the extremities
was detected (Rivers and Schwentker 1935). This was the first evidence that a
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demyelinating disease could be triggered by vaccination with brain tissue and
thus excited the MS community.
In modern EAE protocols, whole brain homogenates are no longer used.
Rather, specific immunogenic myelin peptides are injected with Freund’s
adjuvant (immunostimulatory, inactivated mycobacteria) along with pertussis
toxin which weakens the BBB (Stromnes and Goverman 2006). This vaccination
model represents the Active Induction EAE model, and is characterized by an
ascending flaccid paralysis with CD4+ T cell mediated inflammation targeting
the spinal cord. Along side Active Induction there is also a Passive Induction
model in which myelin reactive CD4+ cells are adoptively transferred from a
vaccinated animal into a naïve animal, again leading to ascending flaccid
paralysis with a predilection for the spinal cord (Stromnes and Goverman 2006).
One striking inconsistency between EAE and MS is that EAE animals
suffer from a flaccid paralysis while MS patients suffer from spastic paralysis
(Stromnes and Goverman 2006). Additionally, clonally restricted CD8+ T cells
dominate MS lesions while both active and passive EAE result from CD4+ T cell
mediated disease (Sriram and Steiner 2005). However, efforts are being made to
develop CD8+ T cell mediated EAE models by engineering recombinant viruses
that express myelin proteins (Stromnes and Goverman 2006). In addition to the
differences in paralysis (flaccid vs. spastic) and effector T cells present in EAE vs.
MS lesions (CD4 vs. CD8), Table 3 lists many of the other differences between
EAE and MS.
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Table 3. Immunopathology and Response to Therapy in EAE and MS. (Sriram
and Steiner 2005)
Table 1. Immunopathology and Response to Therapy in EAE and MS
EAE
Pathology
Location of demyelination

MS

Predominantly, perivenous sleeves of myelin
loss in spinal cord and brain

Location of lesions

Demyelination not restricted to perivenous
regions of white matter; extensive demyelination of cerebral cortex in the absence of inflammation is common
Periventricular areas, cortical mantle,
brainstem, optic nerves, and upper cervical cord; lesions are uncommon in
thoracic and lumbar regions
Activated macrophages and CD8! T cells
of a restricted clonotype
Variable; no clear cytokine preponderance

Dependent on the autoantigen used for induction: inflammation dominates in lumbar regions in MBP and PLP EAE and
brainstem in MOG EAE
Phenotype of cellular infiltrate CD4! T cells (MBP and PLP EAE) activated macrophages and few CD8! T cells
Cytokine predominance
TH1 bias in MBP and PLP EAE; TH2 bias
worsens MOG EAE
CSF immunology
Antibodies to myelin antigens present in CSF Antibodies to myelin antigens are infrequent in CSF and do not constitute the
antigen specificity of oligoclonal bands
Effect of immunotherapies
" interferon
Depends on route of administration and can Worsening of inflammatory lesions uneither worsen on ameliorate EAE
proven
# interferon
Variable; can worsen EAE if given after imDecreases relapse rate: effect on progresmunization
sion modest
Anti–TNF antibody
Reverses EAE
Worsens MS
Anti–VLA-4 antibody
Reverses EAE
Decreases relapses; effect on progression
not known
Anti–CD4 antibodies
Cures EAE
No evidence of clinical efficacy on relapses
or progression

EAE $ experimental allergic encephalomyelitis; MS $ multiple sclerosis; MBP $ myelin basic protein; PLP $ proteolipoprotein; MOG $
myelin oligodendrocyte glycoprotein; CSF $ cerebrospinal fluid.
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to show that in MS cerebrospinal fluid there was intrathecal synthesis of clonally
restricted IgG (Lature 1964). These unique CSF antibodies gave a different
electrophoretic pattern when compared to serum IgG from the same patient.
Oligoclonal bands are not unique to MS, but are present in other
neurologic diseases, typically of an infections or inflammatory origin. In the case
of an identifiable infection, the oligoclonal antibodies usually react with
pathogen-derived antigens that are either found in the brain tissue or are part of
an antigen specific serological assay e.g. an ELISA. Below is a summary of
different gamma globulin banding patterns:
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Figure 9. Gamma Globulin Banding Patterns and Associated Conditions.
Pattern 1 (not shown) is an absence of banding in both the serum and CSF and
reveals an absence of both systemic and intrathecal IgG synthesis. Pattern 2
shows oligoclonal banding in the CSF only and can be seen in MS. Pattern 3 (a
more than pattern) shows oligoclonal banding both in the serum and CSF,
however, there are additional bands in the CSF. Pattern 3 can also be seen in MS
and indicates both systemic and intrathecal IgG synthesis. Pattern 4 (a mirror
pattern) suggests systemic IgG synthesis with an absence of intrathecal synthesis.
This pattern is not usually seen in MS. (University of Birmingham 2013)
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Because the oligoclonal CSF antibodies fail to react against myelin
proteins, as they do viral antigens e.g. SSPE caused by the measles virus,
investigators have wondered if MS CSF antibodies are “nonsense” antibodies
that have been produced as part of a non-specific inflammatory process.
However, Gregory P. Owens et al. have shown that the intrathecal plasma cell
clones that secrete these antibodies have undergone somatic hypermutation,
suggesting a response to a particular antigen (Owens, Kraus et al. 1998).
Furthermore, they have shown binding of human IgG to an unknown antigen at
the edge of MS lesions (Owens, Gilden et al. 2011).

Conflicting data exist

regarding the binding of human IgG in MS lesions, as Barnett et al. conclude that
IgG staining of disrupted myelin in MS lesions is a non-specific feature found in
neurologic diseases other than MS. (Barnett, Parratt et al. 2009).
One provocative study has proposed a bona fide MS autoantigen. In 2012,
Srivastava et al. screened serum IgG from MS patients for antibodies capable of
binding to brain tissue. They identified that 47% of MS patients possessed serum
IgG reactive against the first extracellular loop of the KIR4.1 potassium channel
compared to 1% in patients with other neurologic disease and 0% in healthy
controls (p<0.001). Injection of affinity purified MS IgG (using KIR4.1 as bait) led
to changes in the astrocyte cytoskeleton and complement deposition. Although
oligodendrocytes also express KIR4.1, no evidence of damage to these cells was
reported (Srivastava, Aslam et al. 2012).

Since the anti-astrocyte IgG (anti-

aquaporin 4) is proving to be the primary pathophysiologic mechanism for
Neuromyelitis Optica (NMO) (Roemer, Parisi et al. 2007), another demyelinating
disease, one could argue that anti-KIR 4.1 may be of importance in the
demyelination that occurs in MS. However, NMO and MS differ significantly in
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their pathological features. NMO lesions are characterized by astrocyte loss,
neutrophil and eosinophil infiltration, significant axonal injury and profound
inflammation, where as MS lesions display oligodendrocyte apoptosis, mild
inflammation and minimal axonal injury (Lassmann 2011).

Back to the Basics: Modern Day MS Pathology

Despite important contributions from many disciplines, the cause of MS
still evades us. However, modern advances in MS pathology may hold the key
to unlocking this centuries old mystery. Detailing the cellular changes that occur
soon after the MS lesion begins to unfold gives us the best chance of revealing
key features of the elusive trigger. Two research groups, Lucchinetti/Lassmann
and Barnett/Prineas, have dominated the field for the last 15 years.
Unfortunately, these groups are not in agreement regarding the nature of MS
lesions.

The standard view of MS lesions: MS plaques vary in size and in number but
are most conspicuous in areas with myelin enriched axon tracts, termed white
matter. These areas include the periventricular white matter, the visual system,
deep white matter, brainstem, and spinal cord. Active MS lesions are usually
localized to white matter regions and are characterized by a mixture of lipidladen macrophages, large reactive astrocytes, accompanied by varying
perivascular inflammation. Axons are relatively well preserved, although where
damage is most severe, axons are also lost or fragmented and display irregular
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tortuous and clubbed profiles.

Besides focal demyelinated plaques, global

diffuse injury of the so-called “normal”- appearing white matter (NAWM) is
found in the brains of MS patients.

The pathology of NAWM in MS is

characterized by diffuse, mainly CD8+, T cell infiltrates, gliosis, microglial
activation, diffuse axonal injury and nerve fiber degeneration. Chronic inactive
MS lesions are hypocellular with no evidence of active myelin breakdown.
Astrocyte proliferation and hypertrophy (reactive gliosis) is prominent and,
although axonal injury is considered mild when compared to the axonal loss
observed in an infarct, some degree of axonal damage can be appreciated.
Mature oligodendrocytes are markedly diminished or absent in chronic inactive
lesions and inflammation, especially in perivascular regions, often remains
(Lucchinetti, Parisi et al. 2005).

MS according to Claudia Lucchinetti/Hans Lassmann: In an analysis of 51
biopsies and 32 autopsy specimens, Lucchinetti/Lassmann concluded that a
profound heterogeneity exists between patients with respect to the inflammatory
response, oligodendrocyte survival and patterns of demyelination. However,
they observed a striking homogeneity among lesions within a given patient. In
their opinion, MS may represent a common name for different pathologic entities
that unify on the special vulnerability of CNS myelin to various immune and
toxic mediators (Lucchinetti, Bruck et al. 2000). The heterogeneous phenotypes
observed in MS patients can be classified into four distinctions:
Pattern I: Macrophage-associated demyelination
Pattern II: Antibody/complement-associated demyelination
Pattern III: Distal dying-back oligodendrogliopathy
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Pattern IV: Primary oligodendrocyte degeneration
Although each pattern involves an inflammatory response composed mainly of T
lymphocytes and macrophages, differences in plaque geography, extent and
pattern of oligodendrocyte pathology, immunoglobulin deposition, complement
activation, and myelin protein loss were observed.
In patterns I and II, macrophages and T cells predominate in welldemarcated plaques that surround veins and venules; only pattern II lesions
demonstrate local precipitation of immunoglobulin and activated complement in
regions of active myelin breakdown. The expression of all myelin proteins is
similarly reduced. Pattern III lesions also contain an inflammatory infiltrate,
composed of macrophages, activated microglia and T cells; however, the lesions
are ill defined and seldom surround vessels.

There is no evidence of

immunoglobulin deposition or complement activation, and Myelin Associated
Protein (MAG) is selectively lost compared to other myelin proteins. MAG is a
myelin protein localized to the most distal extension of the oligodendrocyte cell
body (the periaxonal region), and early loss of this protein is believed to reflect a
dying-back phenomenon in the oligodendrocyte, which precedes the apoptosis
found to be prevalent in pattern III. Pattern IV lesions also contain T cells and
macrophages but no preferential MAG loss, immunoglobulin deposition or
complement activation is observed. Instead, there is evidence of non-apoptotic
oligodendrocyte death, the mechanisms of which are unclear. In summary, interindividual rather than intra-individual differences in lesion heterogeneity with
respect to demyelination is a characteristic feature of MS (Lucchinetti, Parisi et al.
2005).
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A rebuttal to the Lucchinetti/Lassmann model: Although a provocative concept,
the heterogeneity of MS lesions as described by Lucchinetti and Lassmann has
come under question. Breij et al. analyzed 131 lesions from 39 patients with
long-standing MS. The aim of the study was to determine if inter-individual
differences persist in patients who are temporally farther away from their first
symptoms. They found a homogenous pattern of demyelination in active lesions
in

patients

with

long-standing

MS.

The

authors

suggest

that

the

immunopathological appearance of active demyelinating lesions in established
MS is uniform. Initial heterogeneity of demyelinating lesions in the earliest phase
of MS lesion formation may disappear over time as different pathways converge
in one general mechanism of demyelination (Breij, Brink et al. 2008).

MS according to Michael Barnett/John Prineas: In an analysis of 10 lesions
collected hours-days after the deaths of 7 patients with fatal MS lesions (the
earliest lesion being 17 hours old), Barnett/Prineas concluded that newly
forming lesions arise in the absence of an inflammatory infiltrate. Instead, there
was evidence of primary oligodendrocyte degeneration/apoptosis, BBB
breakdown and early microglial activation. In their opinion, some local change
to which oligodendrocytes are uniquely susceptible is responsible for lesion
formation (Barnett and Prineas 2004). They offer the following timeline: Within
hours of lesion initiation, oligodendrocytes throughout the affected tissue appear
apoptotic (as shown in Figure 10), myelin sheaths stain positively for activated
complement while immunoreactivity for CNP and MAG is diminished, and
ramified microglia with thickened processes appear in increased numbers. T
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cells, early-activated macrophages and myelin phagocytes are rare or absent in
the apoptotic zone but are present elsewhere in the lesion. After 1 or 2 days,
oligodendrocytes disappear, most presumably phagocytosed by the now
amoeboid microglia present in the tissue. The tissue appears vacuolated because
of the presence of widespread intramyelinic edema, which is the usual
accompaniment of oligodendrocyte loss. The third and most protracted stage
involves fragmentation and uptake of vacuolated and smudged (vesiculated)
myelin sheaths by macrophages in the presence of infiltrating T cells and
macrophages (Barnett and Prineas 2004).
Surprisingly, Barnett and Prineas were not the first to describe apoptotic
oligodendrocytes and early microglial activation in the absence of an
inflammatory infiltrate. In 1952, Adams and Kubik described a lesion, which
they estimated was 48 hours old. In this newly forming lesion, they observed
unstained or poorly stained, but still intact myelin, and pyknotic nuclei, which
they attributed to degenerating oligodendrocytes. They went on to postulate
that the process that damages the myelin, at the same time destroys
oligodendrocytes and causes a microglial reaction. Most importantly, there was
no perivascular infiltration in this early lesion (Adams RD 1952).
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In contrast to Lucchinetti/Lassmann, Barnett/Prineas conclude that these
“prephagocytic” oligodendrocyte changes represent the initial process for all MS
lesions and that inter-individual lesion heterogeneity does not exist.
Furthermore, they argue that the Lucchinetti/Lassmann findings represent
different temporal stages in lesion evolution. While Barnett and Prineas admit
that their study provides no direct evidence for what might be the cause of
oligodendrocyte apoptosis, they point out that one unexplained finding that may
relate to the genesis of a new lesion is the occasional occurrence of perivascular
cuffs of mononuclear cells adjacent to periventricular white matter, at the
corticomedullary junction and close to the pia, all areas where new MS lesions
tend to form (Barnett and Prineas 2004). Furthermore, Barnett and Prineas report
serum protein leakage and the accumulation of perivenular monocytes in the
absence of oligodendrocyte apoptosis or demyelination. These data suggest that
insult of the endothelium and a subsequent innate immune response may be the
earliest of changes in acute MS lesions. (Prineas and Parratt 2012)

Resurrecting The Vascular Theory of MS

Although these newly forming lesions lacked an inflammatory infiltrate
within the CNS proper, the fact that immune cells were found to congregate
around CNS vasculature in normally appearing white matter may be telling.
There has been long-standing interest in a vascular hypothesis for the genesis of
the MS lesion dating back to the mid-1800s when Eduard Rindfleisch (1836-1908)
noted, in 1863, the consistent location of a blood vessel in the center of MS
plaques. Rindfleisch, later followed by Prineas and others, observed cellular
37

infiltrates that remained confined to the perivascular space. He postulated that
MS was caused by a primary insult to CNS blood vessels and their ramifications,
and that the perivascular infiltrates were secondary to this primary insult.
Rindfleisch writes:
If one looks carefully at freshly altered parts of the white matter…one
perceives already with the naked eye a red point or line in the middle of
each individual focus…the lumen of a small vessel engorged with
blood…All this leads us to search for the primary cause of the disease in an
alteration of individual vessels and their ramifications; all vessels running
inside the foci, but also those which transverse the immediately
surrounding but still intact parenchyma are in a state characteristic of
chronic inflammation. (Eduard Rindfleisch, 1863)
In accordance with this vascular theme, Dawson’s seminal 1916 thesis on
the pathology of MS ultimately concluded that MS is likely caused by a soluble,
hematogenous toxin that enters the CNS due to an unknown vascular
abnormality (Dawson 1916). Here Dawson summons both the vascular theory,
originated by Eduard Rindfleisch and the soluble toxin theory, originated by
Byrom Bramwell.
Published data support a vaso-centric interpretation of MS with MSassociated retinal phlebitis perhaps being the most intriguing example. Retinal
phlebitis is the inflammation of the venules and veins of the retina. The retina
resembles the brain and spinal cord in that it consists of neurons, astroglia
(muller cells) and vasculature that restricts the free flow of solutes from the blood
into its parenchyma, the blood-retinal barrier (BRB). Most importantly, the
retina lacks oligodendrocytes, the myelin forming cells of the CNS, and thus
lacks myelin. Therefore, inflammation of the retinal vasculature cannot be
secondary to a demyelinating process. Despite this lack of myelin, many
researchers have observed inflammatory scarring of the retinal microvasculature
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(Kerrison, Flynn et al. 1994). This phenomenon remains unexplained.
Ter Braal and Herwaarden first reported MS associated retinal phlebitis in
1933 (Kerrison, Flynn et al. 1994). Since their initial observation, two types of
inflammatory scar or “sheathing” have been described, active and inactive.
Active venous sheathing consists of infiltrates that disappear over a period of
months to as long as two years. Inactive venous sheathing consists of sharp,
well-defined, permanent lines along veins; a presumed sequelae of chronic,
active phlebitis. Inactive sheathing causes the venular walls to become thick and
laminated with collagen. This occurrence has been the subject of a number of
clinical studies, and the frequency of venous sheathing has been estimated to be
between 9% and 36%. Furthermore, a multi-study analysis of the frequency and
duration of venous sheathing predicts a frequency of 11.5% and an average of 3.6
episodes during the course of the disease (Kerrison, Flynn et al. 1994).
In addition to venous sheathing of the retinal veins, ocular coherence
tomography (OCT) studies have identified retinal abnormalities in MS patients
even though the retina lacks myelin. Investigators have identified an increased
thickness of the inner nuclear layer (INL) of the retina, which correlates with
increased disease activity and contrast enhancing MRI lesions. In the same
study, they also found evidence of microcystic macular oedema (MMO)
suggesting a break down of the blood-retinal barrier (BRB), which is analogous
to the blood-brain barrier in the brain (Runkle and Antonetti 2011). The authors
mention that BRB breakdown occurs in approximately 20% of MS patients and
occurs concurrently with BBB breakdown during active disease (Saidha,
Sotirchos et al. 2012).
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Blood-retinal barrier dysfunction is not the only provocative vascular
abnormality that has been observed in MS. Other investigators have described
early evidence of microvascular injury in acute MS lesions. Despite these
vascular lesions, the surrounding myelin remains preserved and the reactive
changes in the cerebral parenchyma are absent (Adams, Poston et al. 1985;
Wakefield, More et al. 1994). This early damage to the CNS microvasculature
has been described as focal endothelial cell associated fibrin deposition, which
can be found in many thin-walled vessels, including veins and capillaries.
Investigators of this phenomenon suggest that activation of the cerebral
endothelium is a primary event in MS (Adams, Poston et al. 1985; Wakefield,
More et al. 1994).
Vascular inflammation in the absence of demyelination, and even in the
absence of myelin itself, as observed in retinal phlebitis, raises three important
questions:
1. What causes the vascular injury observed in MS patients?
2. Why is the CNS vasculature targeted while the peripheral vasculature is
spared?
3. Is the demyelination that typifies the MS lesion secondary to the vascular
insult or is it a separate process?
Because the primary role of blood vessels is to transport molecules and
cells throughout the body, the idea that a soluble, blood-borne, noxious agent
may trigger MS quickly followed Rindfleisch’s mid-19th century vascular theory.
Two of the most influential MS researchers of the early 20th century, Dawson and
Marburg, supported the soluble toxin theory.
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Both Dawson and Marburg were struck by the reproducibly close
proximity of MS plaques to the ventricular system and the equally reproducible
presence of a vein or venule at the center of a lesion. Dawson also commented
on the remarkable symmetry of periventricular plaques in MS. He explained this
distribution on a vascular basis and concluded that MS was due to a specific
morbid agent, probably a soluble toxin, which is conveyed to the nervous system
by the blood channel (Dawson 1916; McAlpine 1946). Similarly, Marburg
speculated that the causative agent might be an enzyme or immuno-agent that
diffuses from the blood or CSF into the brain (Adams, Poston et al. 1985).
Although the soluble toxin theory’s popularity peaked in the early 20th
century, current data has re-invigorated this past theory. The advent of more
advanced myelin stains and MRI imaging techniques has made clear that MS
lesions are not confined to the subcortical white matter. Indeed, modern
research has shown that cortical demyelination exists and this demyelination
occurs in a very interesting pattern. Cortical lesions typically emanate from the
subpial surface (the area of the brain that is in direct contact with the CSF).
Additionally, these lesions typically occur as long strips (Figure 11), suggestive
of a diffuse process, in contrast to the focal characteristics seen in subcortical
white matter lesions with a venular or capillary focus (Rudick and Trapp 2009).
Dr. Bruce Trapp maintains that a soluble and diffusible agent may be at play
(personal communication), an inference that revisits the conjecture of his 20th
century predecessors, Bramwell, Dawson and Marburg. In support of this view,
Lassmann et al. found that cortical lesions predominantly occur in deep
indentations of the cortical ribbon and in cortical sulci, and this is consistent with
a soluble mediator as cerebrospinal fluid flow is more restricted in these areas
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than at the outer cortical surface (Lassmann 2011). It should be noted, that Trapp
and Lassmann believe this soluble mediator to be derived from inflammatory
cells residing in the meninges (Rudick and Trapp 2009; Lassmann 2011).
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Figure 1. Model of Lesion Formation in M

Figure 11. A Ribbon-Like, Sub-Pial Gray Matter MS Lesion. (Rudick and
Trapp 2009)

Demyelinating lesions in the cerebral cor
Derfuss and colleagues5 recently describe
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trigger the pathologic process. In pattern

CHAPTER 2

Could Clostridium perfringens Epsilon Toxin Be a Soluble MS Trigger?

To expand the vascular/soluble toxin theory, I wish to return to questions
raised in the previous chapter. If we accept that vascular inflammation occurs in
the absence of demyelination (perivascular cuffs in normal appearing white
matter) and in the absence of myelin itself (retinal phlebitis and microcystic
macular edema) then the below questions naturally follow:
1) What causes the vascular injury observed in MS patients?
2) Why is the CNS vasculature targeted while the peripheral vasculature
is spared?
3) Is the demyelination that typifies the MS lesion secondary to the
vascular insult or is it a separate process?
In this chapter, I will suggest that a soluble bacterial toxin, epsilon toxin
(ETX) derived from Clostridium perfringens types B and D, adequately addresses
each of these fundamental questions.
C. perfringens is a gram positive, spore forming, anaerobic rod that is subcategorized into five toxinotyopes based on combinatorial carriage of α (plc), β
(cpb1), ε (etx) and ι (iap/ibp) toxins. Clostridium perfringens enterotoxin (cpe)
and β2 (cpb2) are considered major Clostridial toxins but do not factor into the
toxinotype classification. Unlike other Clostridial species, C. perfringens is nonmotile and does not invade host tissue. C. perfringens is wide spread in the
environment and can be readily found in soil and sewage (McDonel 1980). It is
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also commonly found in the intestines of animals, including humans where it can
be pathogenic under certain conditions (Rood and Cole 1991).
In humans, C. perfringens causes gas gangrene, gastrointestinal disease e.g.
food poisoning (cpe toxin) and necrotic enteritis (β toxin), whereas in other
animals, enterotoxaemic diseases occur more frequently. While C. perfringens
does not invade tissues, it produces a variety of toxins and enzymes responsible
for the associated lesions and symptoms. The toxins produced depend on the
particular C. perfringens toxinotype involved and each toxin produces a specific
syndrome (Table 4) (Petit, Gibert et al. 1999).
	
  
REVIEWS
Table 4. Diversity of Clostridium perfringens Toxinotypes, Genotypes and
Associated Diseases. (Petit, Gibert et al. 1999)
Table 1. Diversity of Clostridium perfringens toxinotypes, genotypes and associated diseases
Toxinotype
!

Major toxina
"
#
$

Genotype

Humans

Associated pathologyb
Others animals

A

)) *

*

*

plc
plc, cpe
plc, cpb2d
plc, cpb2, cpe

B

)

)

)

*

plc, cpb1, etx
plc, cpb1, etx, cpe

C

)

)

*

*

plc, cpb1
plc, cpb2
plc, cpb1, cpe
plc, cpb2, cpe
plc, cpb1, cpb2
plc, cpb1, cpb2, cpe

D

)

*

)

*

plc, etx
plc, etx, cpe

Enterotoxemia in lambs,
sheep, calves and goats

E

)

*

*

)

plc, iap, ibp
plc, iap, ibp, (cpe)f
plc, iap

Enterotoxemia in calves

Gangrene
Gastrointestinal diseasesc (food
poisoning, antibiotic-associated
diarrhea, sporadic diarrhea,
some cases of sudden infant
death syndrome)

Diarrheac (foals, pigs...)
Necrotic enteritis in fowl

Dysentery in newborn lambs
Hemorrhagic enteritis in
neonatal calves and foals
Enterotoxemia in sheep
Necrotic enteritis (Pigbel,
Darmbrand)e

Necrotic enteritis in piglets,
lambs, calves and foals
Enterotoxemia in sheep

Toxinotypes based on mouse lethality tests.
Data taken from Refs 2–4,7.
Caused by enterotoxigenic strains.
d
Some strains containing the cpb2 gene are classified as type A by the mouse lethality test.
e
C. perfringens type C necrotic enteritis has been observed in New Guinea populations (Pigbel) and in Germany after World War II (Darmbrand).
f
Gene in brackets is not expressed.
a
b
c

requires an accurate correspondence between the
toxinotype of the strain used for the vaccine and that
found in clinical isolates.
Toxin-encoding genes
Most of the virulence genes from C. perfringens have
been characterized (Table 2). The genes encoding

and one copy of IS1469 (related to IS200 from Gramnegative bacteria) immediately upstream of the cpe
4419. When localized on a plasmid, the cpe gene is
gene
flanked by IS1469 and, in some strains, by another
insertion sequence, IS1151 (Ref. 17). The etx gene,
encoding the &-toxin, is also linked to IS1151 (Refs
13,20). This suggests that cpe and etx are, or have

C. perfringens type A is ubiquitous, is the most common of the toxinotypes
and is commensal to the human gut. Approximately 50% of healthy North
Americans harbor intestinal C. perfringens type A (Carman, Sayeed et al. 2008).
However, the distribution of the other toxinotypes is more restricted. Types B
and D are predominantly found in ruminants; type C in pigs and type E in
calves. Host specificity probably depends on particular host factors and specific
bacterial virulence factors e.g. adhesins that promote digestive tract colonization.
Although adhesins have not been identified for C. perfringens, it has been
reported that toxinotype C adheres to intestinal villi (Walker, Murrell et al. 1980).
Additionally, bacterial enzymes involved in utilizing certain substrates could
promote rapid growth in the digestive tracts of specific animals e.g. in
Bacteroides sp. the locus containing α-galactosidase and a regulatory gene for
polysaccharide utilization are critical for the colonization of the mouse digestive
tract (Petit, Gibert et al. 1999).
Interestingly, type A is the dominant toxinotype in soil where it is
thought to outcompete the minor toxinotypes for resources. It appears that the
minor toxinotypes (B, C, D and E) depend on a mammalian host for survival
(Itodo, Adesiyun et al. 1986), however, the host-pathogen interactions that
dictate toxinotype/species coupling are poorly understood. Even when the
minor toxinotypes (of intestinal origin) are inoculated directly into soil, they die
out within a few months as they cannot compete with the better adapted normal
soil inhabitants (McDonel 1980).
Of the seventeen toxins that C. perfringens secretes, ETX is the most potent,
trailing only Clostridium botulinum and tetanus toxins in lethality (Popoff 2011).
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C. perfringens types B and D, which typically colonize the G.I. tract of sheep,
goats and cattle but not man, carry two unique extrachromosomal ETX plasmids
(Havard, Hunter et al. 1992) and secrete ETX upon exponential bacterial growth.
Secreted as a 33kDa inactive precursor within the ruminant intestine, ETX is
cleaved by trypsin, chymotrypsin and/or an additional clostridial exotoxin,
lamda toxin. Proteolysis removes 11-13 N-terminal amino acids and 29 Cterminal amino acids yielding a 31kDa cleavage product that is 1000X more
active. Activated ETX permeablizes the gut epithelium, enters the blood stream
and binds to an unknown receptor on the luminal surface of brain endothelial
cells (Figure 12). Once bound to brain microvascular, ETX breaks down the BBB
resulting in cerebral edema (Popoff 2011). For this reason, ETX has been
classified a category B select agent and a bioterrorism threat (Bokori-Brown,
Savva et al. 2011).

Figure 12. ETX Binds to BBB Vasculature. A sheep brain section incubated with
GFP-ETX fusion protein. White arrows indicate ETX binding to brain
vasculature in the brain slice. (Dorca-Arévalo, Soler-Jover et al. 2008)
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In addition to its known effects on BBB vasculature, ETX has been found
to specifically bind to myelin when incubated with mammalian brain slices
(Figure 13) (Dorca-Arévalo, Soler-Jover et al. 2008). We have also confirmed this
finding in the mouse brain (Figure 14). Furthermore, we find that incubating
mixed glial cultures with active ETX causes selective damage to
oligodendrocytes (Figure 15). Interestingly, cultured oligodendrocytes that make
physical contact with microglial cells display increased sensitivity to ETX
(picomolar range), displaying membrane blebbing and extensive morphological
changes. However, cultured oligodendrocytes that have no contact with
microglial cells display ETX sensitivity in the nanomolar range and cell death is
typified by detachment of the cell body from the substrate, leaving the processes
attached to the dish (data not shown). In summary, this unique ability to interact
specifically with the tissues that are damaged in MS, the BBB and the CNS
myelin-oligodendrocyte unit, makes ETX a promising candidate as an
environmental MS trigger.

47

Figure 13. ETX Binds to White Matter. A sheep brain section incubated with

)LJXUH
&OLFNKHUHWRGRZQORDGKLJKUHVROXWLRQLPDJH

GFP-ETX fusion protein. White arrows indicate ETX binding to brain
vasculature in the brain slice. (WM) indicates ETX binding to a myelinated white
matter region of the sheep brain. (Dorca-Arévalo, Soler-Jover et al. 2008)

Figure 14. ETX Binds Specifically to Myelin. Fixed frozen coronal sections from

vine nervous system.
Sections
sheep (A,
and C)
and bovine
(D) brains
were incubated with eadult
mouse from
brain through
theBcorpus
callosum
were stained
for proteolipid
owing the bindingprotein
of e-prototoxin-GFP
the 594-ETX
white matter
(WM) staining
and blood
(PLP, green), andto
Alexa
(red). Intense
withvessels
ETX is (arrows). (B)
owing the bindingobserved
of e-prototoxin-GFP
to myelin structures (WM) and blood vessels (arrows). (C)
in all PLP-positive white matter tracts. Merged PLP and ETX images
ar layer of the sheep cerebellum stained with the e-prototoxin-GFP. (D) A section of the bovine
reveal essentially complete overlapping fluorescent signal. Bar = 200 um.
otoxin-GFP to myelin structures (WM) and blood vessels (arrow). WM: white matter; GL: granular
olecular layer. Scale bars: A and C, 75 mm; B: 40 mm; D, 25 mm.
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orca-Arévalo, J., et al., Binding of e-toxin from Clostridium perfringens in the nervous
:10.1016/j.vetmic.2008.02.015

A.

B.

Figure 15. ETX Kills Cultured Oligodendrocytes. A) Untreated mixed glial
culture from rat brain, oligodendrocyte (left) and microglial cell (right). B) Mixed
glial culture from rat brain treated with 600pM ETX overnight, oligodendrocyte
(top), microglial cell (bottom). Note the swelling of the oligodendrocyte cell
body, blebbing of the membrane and damaged processes. The microglial cell
below shows no signs of injury.
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In fact, ETX has been proposed as an MS trigger in the past. Reviewing
the idea that MS is associated with the concentration of global sheep populations,
Dr. Timothy Murrell identified historically aberrant MS outbreaks and proposed
that these epidemics stemmed from human contact with sheep (Murrell,
O'Donoghue et al. 1986). He went on to delineate pathogens that may be
transmitted from sheep to humans. Intriguingly, he offered C. perfringens type D
as a possible infectious agent, as sheep are the natural reservoir for this
bacterium. Importantly, humans typically carry C. perfringens type A, which
does not carry an ETX encoding plasmid (Carman, Sayeed et al. 2008).
Murrell notes that ETX causes MS like symptoms upon entering the
animal’s blood stream such as blindness, ataxia, opisthotonos (a form of spastic
paralysis) and central nervous system derangement due to malacia in brain areas
with a distribution similar to MS; periventricular lesions perhaps being the most
provocative, as they are commonly observed in both ETX intoxicated animals
and MS patients (Murrell, O'Donoghue et al. 1986). Murrell concludes by
suggesting that ETX mediated BBB breakdown may open the human CNS to a
demyelinating neurotropic virus resulting in MS. However, the 2008 finding that
ETX specifically binds to myelin once it gains access to the CNS may obviate the
need for a neurotropic virus to cause demyelination.
There are many other properties of ETX that make it an attractive
causative agent for MS. ETX mediated veterinary disease bears the name focal
symmetrical encephalomalacia (FSE), and if one examines the meaning of this
clinical term, similarities between FSE and MS start to emerge. The characteristic
subcortical white matter MS lesion is indeed focal in nature, matching the
pathologic description of FSE. MS lesions are often symmetrical, especially
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lesions that form close to the lateral ventricles (McAlpine 1973). Finally,
encephalomalacia literally means “brain softening,” while sclerosis means “scar”
or “hardening.” Although these two terms seem to oppose each other, sclerosis
is indeed a misnomer when it comes to MS. One must consider that MS lesions
harden over time. In reality, fresh MS lesions that are in the processes of forming
during the active disease state are soft. The earliest of MS investigators Carswell,
Cruveillhier and Dawson noted that fresh lesions were softer than the normal
brain substance. Therefore, in terms of active disease, “encephalomalacia” more
accurately describes MS than “sclerosis”(Murray 2005).
The experimental injection of rodents with ETX also shows many
provocative parallels to the MS disease state. ETX not only binds specifically to
brain microvessels, but also has a penchant for vasculature residing in the
myelinated regions of the brain (Finnie 1984). Additionally, intoxicated mice
often develop periventricular lesions, similar to the lesion distribution seen in
MS (Figure 16) and display a form of spastic paralysis evinced by neck
retroflexion (Morgan and Kelly 1974). Similarly, MS patients often suffer from
spastic paralysis, typically of the lower limbs. In this way, ETX intoxication may
better characterize MS than the current EAE model. EAE mice develop a flaccid
rather than the spastic paralysis that occurs in MS (Stromnes and Goverman
2006; Stromnes and Goverman 2006).
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366

J.

W.

FINNIE

Figure 16. ETX Causes Periventricular Lesions. A coronal brain section of a
mouse injected with ETX shows bilateral periventricular lesions and a lesion in
the corpus callosum. (Morgan and Kelly 1974)
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within the corpus callosum, in which the long axis of the ovoid is oriented

perpendicular to the surface of the lateral ventricle (Zhu, Ghabriel et al. 2001).

These ETX induced lesions resemble the flame-like lesions that radiate from the

lateral ventricles in MS, termed Dawson’s fingers (Figure 17). Dawson first

described this specific lesion morphology and the radiographic equivalent is all

but pathognomonic for clinically definite relapsing remitting multiple sclerosis

(Dawson 1916). To date, no MS animal model reproduces this highly specific

lesion morphology.

Figure 17. ETX Recapitulates Dawson’s Fingers. A comparison of MS Dawson’s

(CC). Focal lesions are also seen in the cortex (CX).
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fingers shown on sagittal MRI, left panel (SCIENCEphotoLIBRARY) and ovoid

lesions in ETX precursor injected rats, middle and right panels (Zhu, Ghabriel et

al. 2001). Sagittal sections of the rat brain (middle and right) show that BBB

breakdown occurs with ovoid lesions appearing throughout the corpus callosum
t h e pr ot ot oxin a lon e wou ld h a ve been over sh a dowed by
t h e fa st er a n d st r on ger a ct ion of t h e su bsequ en t ly in ject ed t oxin . In t h e cu r r en t st u dy, a n im a ls wer e a llowed t o su r vive for per iods r a n gin g fr om 1 h t o 14 da ys

st r on ger r espon se wit h sign ifica n t r edu ct ion in im m u n or ea ct ivit y. Th e gr ou p in ject ed wit h t h e lower con cen t r a t ion sh owed m ild a n d la t e r espon se, wh er e t h e m a xim u m effect wa s seen qu a n t it a t ively a t 7 da ys post -

F IG. 6. Ligh t m icr ogr a ph s of sa git t a l sect ion s of wa x-em bedded br a in s fr om con t r ol (A) a n d exper im en t a l a n im a ls (B–F ) in ject ed wit h
pr ot ot oxin . Th e sect ion s sh ow im m u n ost a in in g for en dogen ou s a lbu m in wit h n ickel en h a n cem en t , bu t wit h n o cou n t er st a in in g. In con t r ols
(A) n o a lbu m in im m u n or ea ct ivit y is seen . At 1 h (B) post in ject ion sligh t im m u n or ea ct ivit y is seen especia lly in t h e cor pu s ca llosu m . At 2 da ys
(C) im m u n or ea ct ivit y is visible a s m u lt iple foci of per oxida se r ea ct ion pr odu ct in t h e cor pu s ca llosu m a n d t h e cer ebr a l cor t ex (a r r ows). At 4
da ys (D) a n d 7 da ys (E ) im m u n or ea ct ivit y is st ill h igh er t h a n t h e con t r ol (A) especia lly in t h e wh it e m a t t er (a r r ow). At 14 da ys (F )
post in ject ion on ly occa sion a l foci of im m u n or ea ct ivit y a r e seen (a r r ow). CC, cor pu s ca llosu m ; CX, cor t ex. Ba r , 200 !m .

ZH U E T AL.

Strikingly, intraperitoneal injections of rats with the ETX precursor

protein, which is 1000X less active, results in the formation of focal ovoid lesions

The fact that ETX can disrupt the BBB, bind to myelin, damage cultured
oligodendrocytes, and recapitulate Dawson’s finger lesion morphology and the
spastic paralysis seen in MS are all provocative findings. However, if we look
more closely at the mechanism by which ETX damages cells and compare this to
what Barnett and Prineas observed in newly forming MS lesions more
similarities become clear.
ETX forms heptameric pores in the cell membrane and allows the free
flow of ions, water and hydrophilic solutes (up to 1kDa) across the cell
membrane. This osmotic imbalance causes cellular swelling, membrane blebbing
and cellular damage. ETX toxicity also leads to ATP depletion, AMP-activated
protein kinase stimulation, mitochondrial membrane permeabilization and
mitochondrial-nuclear translocation of apoptosis-inducing factor, which is a
potent caspase 3-independent cell death mechanism characterized by a marked
reduction in nuclear size and nuclear pyknosis (Popoff 2011). Barnett and
Prineas, reported swelling of the oligodendrocyte cell body and the myelin
sheath. More interestingly, they found a reduction nuclear size and nuclear
pyknosis (Figure 10) and caspase 3-independent cell death (Barnett and Prineas
2004), all of which are reminiscent of the type of cell death described in ETX
mediated cytotoxicity.

As previously mentioned, the retina contains no myelin yet retinal
vasculitis, microcystic macular edema and thickening of the retinal inner nuclear
layer (INL) mysteriously occur in MS, all pointing to a primary insult of the BRB.
Because the BRB is analogous to the BBB, which is broken down with every new
MS lesion, it is tempting to postulate that primary damage to CNS vessels occurs
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in MS. Although ETX is known to bind to and break down the BBB, its effects on
the BRB have not been studied. We find that ETX stains retinal vessels when
!"#$%&'()'*+',--"./+'0/'111',+-'23&4"+5'678',49/':"+-9'0/'0;&':4//-<%&.+,4':,%%"&%'
incubated with retinal cryosections (Figure 18), further supporting a potential
role for ETX as an MS trigger.
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Figure 18. ETX Binds to Retinal Vessels. (Left panel) FITC labeled BSL1 (green),
a pan-vessel marker, staining retinal vessels. (Middle panel) Alexa 594 labeled
ETX (red) staining retinal vessels. (Right panel) a merge and enlargement of
staining in the white boxes of the left and middle panels. BSL1 and ETX co-label
a retinal vessel.

Although a promising hypothesis, several caveats must be addressed
when considering ETX as a possible MS trigger. First, in addition to binding CNS
myelin, ETX has been shown to bind to peripheral nerve myelin when incubated
with sciatic nerve tissue slices (Dorca-Arévalo, Soler-Jover et al. 2008), however,
MS is a disease that is restricted to the CNS. Radiolabeled ETX injected into mice
only targets the CNS, and not the PNS (Tamai, Ishida et al. 2003) . We propose
that ETX fails to bind to PNS endothelial cells that comprise the blood-nerve
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barrier; therefore PNS myelin is not accessible to the toxin in vivo.
Second, one might expect GI discomfort and intestinal lesions in MS if
caused by C. perfringens overgrowth and toxin production in the gut lumen.
However, histological abnormalities are minor, inconsistent and often completely
undetectable in intoxicated sheep. Diarrhea is also very uncommon in sheep
enterotoxaemia. The same is not true for intoxicated goats that often suffer from
hemorrhagic enterocolitis and diarrhea (Blackwell, Butler et al. 1991; Fernandez
Miyakawa and Uzal 2003). Therefore, even between ruminants, there is great
species variation in the phenotype of ETX enterotoxaemia.
Interestingly, subtle small bowel changes have been observed in MS
patients (Lange and Shiner 1976). Lange and Shiner reported varying degrees of
villus atrophy, inflammatory cell infiltration and thickening of connective tissue
in an analysis of jejunal biopsies from 12 randomly chosen MS patients.
Third, enterotoxaemia in sheep, goats and less frequently cattle often
results in severe, often fatal disease. MS attacks, while debilitating, are rarely
fatal. Why this difference in disease severity? Attempts to develop a small
rodent oral inoculation model for C. perfringens enterotoxaemia may help
address this question. When inoculated with toxinogenic C. perfringens type D,
mice remain unaffected unless the anus is sealed to halt intestinal transit
(Fernandez-Miyakawa, Sayeed et al. 2007). The authors propose that there may
be more stasis in the ruminant gut, which allows for increased toxin
accumulation and systemic absorption. Additionally, they propose that the
ruminant animal has a larger gut absorptive surface area/body weight ratio than
the mouse, thus making enterotoxaemia more likely in the ruminant (FernandezMiyakawa, Sayeed et al. 2007).
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Furthermore, when toxinogenic C. perfringens strains were orally
administered to germ free guinea pigs, all animals showed signs of intoxication,
however, when this experiment was repeated in conventional guinea pigs with
normal gut flora, none of the animals showed symptoms of intoxication (Horton,
Madden et al. 1970). Therefore, a normal gut flora is protective against
enterotoxaemia. This may be of importance in animals (humans and small
rodents) for which C. perfringens types B and D are not natural symbionts. It
should be noted that germ free animals inoculated with C. perfringens type A,
which is commensal to humans, remained unharmed but toxinogenic types B, C,
D and E all resulted in a fatality rate of 100% (Horton, Madden et al. 1970).
Finally, ETX intoxication often bears the name pulpy kidney disease
suggesting damage to the kidneys. There is no evidence of kidney damage in
MS; however, pulpy kidney disease is a misnomer. The pathological changes in
the kidneys of intoxicated sheep have been shown to be a post-mortem change
characterized by rapid autolysis of the renal tubules. Kidneys that are inspected
shortly after death show minimal, if any signs of damage (Popoff 2011).
In contrast to what the name “pulpy kidney” disease may suggest, the
kidneys have been shown to be critical to ETX detoxification. Nephrectomy of
ETX intoxicated mice greatly increases morbidity, mortality and decreases the
LD50. Therefore, the kidneys are actually key players in ETX host defense
(Tamai, Ishida et al. 2003).
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Have MS patients been exposed to ETX?

Dr. Timothy G.W. Murrell, a general practitioner who considered himself
a “human ecologist,” was the first to suggest a role for C. perfringens epsilon toxin
in MS. Murrell suspected that there was a connection between the prevalence of
MS and global sheep populations. He explored different neurotropic pathogens
that could be transmitted from sheep to humans and he identified C. perfringens
type D/ETX as potential zoonotic MS trigger.
To test this hypothesis of ETX exposure, Murrell harvested blood samples
from MS patients, spouses and age matched control patients with other
neurological disorders. He sent the sera to the Commonwealth Serum
Laboratories (Melbourne, Australia) to be analyzed for circulating levels of antiETX antibodies by a method described in Appendix XIV B8 of the British
Veterinary Codes (Murrell, O'Donoghue et al. 1986). No anti-ETX
immunoreactivities were found by this method.
There are many reasons why this pilot study may have failed. One reason
may be that humoral immunity to epsilon toxin in mammals is transient and
incomplete. For example, when vaccinated at t = 0 and t = 6 weeks with epsilon
toxoid, only 50% of goats have protective anti-toxin titers at week nine. By week
30, at the time of the 3rd vaccination only 2% of the goats maintain protective
titers. At week 32 (2 weeks after the 3rd vaccination), 100% have protective titers,
but by week 56 only 11% show protective titers (Figure 19). Additionally mean
anti-ETX titers follow this same trend of seroreversion (Figure 20). Thus, in
mammals exposed to epsilon toxin, seronegativity and seroreversion are
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common even when the toxin is administered with an adjuvant (Blackwell,
Butler et al. 1983).
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In the following study, we continue Murrell’s work by performing an
immunoreactivity experiment using a Western blot approach. Furthermore, we
determine the prevalence of C. perfringens toxinotypes in MS patients and
healthy controls.

Expt 1. Analysis of ETX Immunoreactivity in MS patients vs. Controls

RESULTS
Increased anti-ETX immunoreactivity in MS vs. controls: We screened sera and
CSF from a cohort of MS patients, healthy controls and other diseases for
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immunoreactivity to ETX by Western blot using the proETX protein. We
developed a Western blot assay that rigorously excluded the likelihood of false
positives. A sample was scored positive if there was clear immunoreactivity for
ETX in conjunction with no immunoreactivity to four control toxins. Three of the
controls were chosen to represent known gut derived toxins: Cholera toxin beta,
Shiga toxin 1 beta and Shiga toxin 2 beta; no cross-reactions ever occurred with
these control toxins. A fourth control, protective antigen 63 (PA63) from Bacillus
anthracis was chosen because like ETX, PA63 is a pore-forming toxin with a
hydrophobicity map similar to epsilon toxin (Knapp, Maier et al. 2009). PA63
was also chosen because most humans should be seronegative. Seroreactivity to
PA63 would occur only in instances of vaccination or exposure to Anthrax. Most
humans are not vaccinated against Anthrax, and in our study, none of the
patients or controls were vaccinated. Seroreactivity to PA63 could also be
observed in people who have been infected with Bacillus anthracis and survived.
Since pulmonary and gastrointestinal Anthrax is usually fatal or debilitating, and
since cutaneous Anthrax results in a characteristic black eschar, it is unlikely that
prior Anthrax would be missed on a directed health questionnaire. Thus,
positive immune reactivity to PA63 would strongly suggest non-specific
interaction of host antibodies with PA63 or prior exposure to an antigen with a
shared epitope. We thus excluded samples that showed immunoreactivity
against ETX and PA63 since these indicated equivocal results. In SLE, where
there is heightened humoral immunity, cross-reactions were common (Figure
21). Since hydrophobic proteins are more likely to show non-specific interactions
with antibodies, we favor the idea that immunoreactivity to PA63 is nonspecific
in nature.
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We found that 10% of MS patients and 1% of healthy controls, in a cross-sectional
analysis, possessed ETX specific antibodies χ2 p = 0.0044 (Figure 21). Based on the
known low rates of seropositivity following immunization, and the common
seroreversion rates, this 10% positivity presumably underestimates the true
value of ETX exposure.

Figure 21. Immunoreactivity to ETX in MS, SLE and Healthy Controls. Left
panel shows Western blots. The two MS blots shown are characteristic for true
positives: immunoreactivity to the C. perfringens proETX protein at 37 kD but not
to the other toxins present on the blot including PA63 at 63kD. The two blots
probed with SLE sera are characteristic of false positives in that
immunoreactivity is also present for PA63. Controls shown are true negatives
with no immunoreactivity to any of proteins present on the blot. Note that the
proETX gene encodes a protein with a predicted MW of 33kD, which runs on
SDS-PAGE with an apparent MW of 37kD. The right panel shows prevalence of
immunoreactivity to ETX in serum and/or CSF of people with MS and healthy
controls.
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Expt 2. Analysis of the prevalence of C. perfringens toxinotypes in MS patients
compared to healthy controls

RESULTS
Reduced prevalence of C. perfringens type A in MS compared to healthy
controls: Soil studies have identified that the presence of C. perfringens type A is
coincident with the absence of other toxinotypes, suggesting that toxinotype A
may compete with other C. perfringens toxinotypes for resources (McDonel 1980;
Itodo, Adesiyun et al. 1986). For these reasons, we assessed the prevalence of
type A, a human commensal, in MS and healthy controls. We cultured feces
from 30 individuals with MS and 31 healthy controls. Bacteria were lysed, DNA
isolated and toxinotypes determined by PCR analysis (Meer and Songer 1997).
Prior published studies have demonstrated that type A is present in
approximately 50% of healthy humans (Carman, Sayeed et al. 2008). Consistent
with this, we found that 52% of the healthy controls (n=31) carried detectable
type A (Figure 22). However, we found only 23% C. perfringens type A carriage
in individuals with MS (n=30), χ2p=0.0227 (Figure 22). This finding supports the
concept that MS susceptibility may, in part, be due to host-microbiome
influences and that the commensal C. perfringens type A may be protective
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Figure 22. C. perfringens type A prevalence in MS and Healthy Controls.
Culture of stool in C. perfringens compatible growth medium revealed that 52% of
health controls harbor C. perfringens type A in the gastrointestinal tract, whereas
only 23% of people with MS harbor type A.

Identification of Clostridium perfringens type B in a woman with Multiple
Sclerosis: A 21-year old woman (patient 73F) developed left lower extremity
dyscoordination, and imbalance that evolved to its maximum deficit over three
days. Two weeks after onset she was referred to a neurologist due to persistent
symptoms and neuroimaging of the brain revealed multiple foci of increased
T2/flair signal in the deep and subcortical white matter, with several ovoid
lesions within the corpus callosum characteristic of MS. Following
administration of IV gadolinium, several lesions enhanced. CSF analysis revealed
five IgG bands on isoelectric focusing that were not present in the corresponding
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serum sample. She met revised criteria for clinically definite relapsing remitting
MS at the earliest clinical presentation termed a clinically isolated syndrome
(CIS). She received five days of IV methylprednisolone, 1 gram per day, and her
symptoms resolved to normal neurological function within three weeks. She
was referred to the Weill Cornell MS Center for confirmation of diagnosis and
treatment planning. Repeat neuroimaging at Weill Cornell revealed lesions
characteristic in morphology and location for Multiple Sclerosis (Figure 23).
Approximately three months after onset of symptoms, she was enrolled in the
HITMS (Harboring the Initial Trigger of Multiple Sclerosis) study, IRB protocol
no. 1003010940, and a self-collected stool sample was obtained. Disease
modifying treatment was initiated. Eight months after initiation of treatment she
remained asymptomatic and her first treatment assessment MRI was performed
which revealed several new contrast enhancing lesions (Figure 23). Three
months after onset of her first symptoms, patient 73F was found to harbor C.
perfringens type B in her GI tract. PCR analysis revealed carriage of genes
encoding α, β, and ε toxins (Figure 24A). This represents the first human known
to carry type B and the first MS patient found to carry an ETX producing C.
perfringens. To exclude a possible laboratory-derived contaminant, we
performed a lysogenic bacteriophage footprint analysis of the laboratory (ATCC
3626) and patient-derived C. perfringens strains. Three lysogenic bacteriophage
insertions were identified in the laboratory strain, which matched the known
whole genome sequence (Figure 24B). The patient’s strain contained just two
lysogenic bacteriophage insertions, thus confirming that the patient-derived ETX
amplicon was not a laboratory contaminant (Figure 24B). Since a combination of
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toxinotypes C and D would also result in identification of α, β, and ε toxin genes,
we sequenced the patient-derived ETX gene confirming that it was derived from
a type B ETX plasmid (Havard, Hunter et al. 1992). Interestingly, eight months
after detection of C. perfringens type B in patient 73F, repeat analysis showed her
to be negative, highlighting the dynamic nature of C. perfringens type B
colonization.

Figure 23. Brain MRI of Patient 73F. (A) FLAIR image from September 2011
showing characteristic lesions in a parasagittal plane. (B-F) MRI from May 2012
revealing characteristic lesions on FLAIR imaging as before (B), T1
hypointensities (C), characteristic contrast enhancing lesions post IV Gadolinium
(D, E), and characteristic lesions on T2 weighted axial image (F).
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Figure 24. C. perfringens type B in Patient 73F. (A) Left panel shows PCR based
genotyping of ATCC 3626 type B strain and from patient 73F. PCR products for
α, β, and ε toxin are identified in both. (B) To exclude the possibility that the type
B strain identified in the stool of patient 73F was a contaminant, the profile of
lysogenic prophage genes was determined in the laboratory strain and in the
patient isolate (right panel). ATCC 3626 reference strain possesses all three
prophage insertions, whereas the patient’s strain possesses only the A6 (weakly)
and N7 prophage insertions. Phage genes and PCR product size: B1RBB5,
1000bps; B1RAA6, 300bps; Q8SBN7, 300bps.

SUMMARY
We propose that C. perfringens ETX fulfills the relevant criteria for an MS
disease initiator. ETX binds to BBB and BRB endothelium (Figures 12 and 18
respectively), disrupts barrier function, binds to white matter (Figure 14) and
damages cultured oligodendrocytes (Figure 15). ETX intoxication also mimics
MS in that it causes Dawson’s finger-like ovoid lesions in the rodent corpus
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callosum (Figure 17) and causes spastic paralysis in affected animals, similar to
the type of paralysis observed in MS. We have found evidence of increased ETX
exposure in MS patients vs. controls. We have identified immunoreactivity to
ETX in about 10% of people with MS vs. 1% in healthy controls, a 10 fold
difference. The low value of immunoreactivity to ETX in MS may be explained
by the difficulty mammals have maintaining humoral immunity to ETX
(Blackwell, Butler et al. 1983). We also find that people with MS are less likely to
harbor C. perfringens type A, a toxinotype thought to outcompete C. perfringens
types B and D for resources in an ecological niche (McDonel 1980; Itodo,
Adesiyun et al. 1986). We have identified one case in which a newly diagnosed
patient harbored C. perfringens type B. This is the first time that a type B
toxinotype has been isolated from a human being and this individual suffers
from MS. Interestingly, eight months after testing positive for C. perfringens type
B, she reverted to negative for all C. perfringens toxinotypes, an example of the
transient nature of bacillus growth and/or detection limits. We expect that
identification of C. perfringens types B or D in humans will be difficult, as C.
perfringens forms endospores that are resistant to standard DNA extraction
methods. Additionally, the organism is likely to exist in low abundance in the
upper GI tract, only rarely entering growth phases that render it detectable.

MATERIALS AND METHODS
Ethics Statement - Research protocol #1003010940 for the collection of samples
from individuals with MS and healthy controls was reviewed and approved by
the WCMC institutional review board. All participants in the study gave written
informed consent.
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Serum and CSF collection - CSF and sera from people with MS and healthy
controls were collected at the Weill Cornell MS Center (IRB protocol no.
1003010940). Additional MS and Stroke CSF and sera were obtained from the
Brain Research Institute, UCLA. SLE sera were purchased from Vital Products
Inc.

ETX immunoreactivity - Western blots were performed using human sera/CSF
as primary antibody (Figure 25). SDS page electrophoresis was run and each
well was loaded with a mixture of 100ng of His tagged proETX (BEI Resources)
and molar equivalents of protective antigen 63 (PA63) from Bacillus anthracis
(EMD Millipore) 190ng, Cholera toxin beta FITC (Sigma Aldrich) 36ng, His
tagged Shiga toxin 1 beta (BEI Resources) 26ng and His tagged Shiga toxin 2 beta
(BEI Resources) 26ng. Proteins were transferred to an Immobilon P membrane
(Millipore) and probed with diluted sera/CSF. All serum and CSF samples were
diluted 10,000 fold and 27 fold respectively, while SLE sera were diluted 100, 000
fold to normalize background. HRP conjugated Donkey anti-human IgG 1:10,000
(Jackson Immunoresearch) was used to visualize human antibody binding.
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Figure 25. A Schematic of The Western Blot Assay. Protein toxins are run on
SDS page and transferred onto an immobilon P membrane. Membranes are
incubated with diluted human antibodies, washed and then incubated in HRPconjugated Donkey anti-human IgG secondary. ECL solution is added and
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immunoreactivity is detected and captured on hypersensitive
) film. (Schematic
adopted from Sigma Aldrich)
Sample collection/Fecal culture/PCR analysis - Stool specimens were self-

collected by patients and healthy controls in a clean single use vessel and stored
at -20 degrees C until returned to the MS Center. Approximately one gram of
stool was collected and stored in a fecal collection tube (Sarstedt) containing 9ml
of buffered glycerin-salt solution (10% glycerin, 71.2mM K2HPO4, 29.4mM
KH2PO4, 71.9mM NaCl made in distilled water, adjusted to pH 7.2 and
autoclaved) under IRB protocol no. 1003010940. Upon receipt, samples were
resuspended in 40ml of modified rapid perfringens media21; D-cycloserine
(400mg/L) was substituted for neomycin/polymyxin Band litmus milk was
omitted to improve DNA extraction. The resuspended samples were cultured in
50ml falcon tubes with tightly closed caps at 47 degrees C ON.
DNA was extracted was from 1ml of culture supernatant using a Qiagen blood
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and tissue kit. Isolated DNA was used as template for the following PCR
reactions; the following primers were used:

1) 16S rRNA (positive control) fwd primer: AGAGTTTGATCCTGGCTCA,
reverse primer: GGTTACCTTGTTACGACTT

2) Alpha toxin (pan C. perfringens marker) fwd primer:
GCTAATGTTACTGCCGTTGA reverse primer: CCTCTGATACATCGTGTAAG
(Meer and Songer 1997)

3)

Beta toxin fwd primer:

GCGAATATGCTGAATCATCTA, reverse

primer: GCAGGAACATTAGTATATCTTC (Meer and Songer 1997)

4)

Epsilon toxin

fwd primer: GCGGTGATATCCATCTATTC, reverse

primer: CCACTTACTTGTCCTACTAAC (Meer and Songer 1997)

5) B1RBB5 phage gene fwd primer: AAATGGACAAGAGGGATAAGGAT,
reverse primer: TTTTCATCACAAATACCAGCCTC

6) B1RAA6 phage gene fwd primer: TTACAATAAAACCACATGAGCTT,
reverse primer: TTTTATTTAACATACTCCGTTTT

7) Q8SBN7 phage gene fwd primer: GGGTGTCAAAGAAGATTTTAAAG,
reverse primer: TTCTATCTTGCAACATTATATTT

71

Statistical analysis - A two-tailed Chi squared test was performed to compare
anti-ETX immunoreactivity in MS patients vs. controls and the prevalence of
commensal Clostridium perfringens type A in MS patients vs. healthy controls.

DISCUSSION
While the above experiments do not prove a causal relationship between
ETX and Multiple Sclerosis, they provide supporting evidence for the ETX/MS
hypothesis. Moreover, we have gathered experimental evidence suggesting that
our current method of culturing C. perfringens from stool samples can be
improved.
Currently, we culture the samples at an increased temperature of 47C,
rather than 37C, which has been shown to favor C. perfringens growth over
competing organisms (Erickson and Deibel 1978). However, this temperature
may not be optimal for all C. perfringens strains. We find that 47C actually
inhibits the growth of our laboratory derived type B strain, but does not affect
the growth of our type A strain (Figure 26).
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Figure 26. Growth Curves of C. perfringens types A and B. Overnight cultures of
type A (ATCC 12915) and type B (ATCC 3626) were cultured at 37 degrees C in
RPM. The following morning, starter cultures were diluted in RPM to an
approximate OD600 of 0.1 and incubated at 37C or 47C.

Furthermore, our culture method seeks to expand C. perfringens that exist as
both vegetative cells and dormant spores in the stool sample. However, selecting
for bacterial spores before culture may increase our sensitivity, as vegetative cells
from other species may outcompete C. perfringens and inhibit its growth. To test
this idea, we re-suspended a patient’s stool sample in rapid perfringens media
and split the diluted sample into two vials of equal volume. One vial was heated
at 80C for 15 minutes to kill the vegetative cells, such that only dormant spores
would remain viable, while the other vial was kept at 25C. Both samples were
then cultured overnight at 47C and we found that the patient was C. perfringens
type A negative by our standard culture method, but C. perfringens type A
positive when dormant spores we selected for by heat treatment (Figure 27).
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We also sought to experimentally determine if C. perfringens toxinotypes
could inhibit each other’s growth as proposed by McDonel and Itodo et al. based
on soil studies showing C. perfringens type A dominance (McDonel 1980; Itodo,
Adesiyun et al. 1986). The fact that healthy controls were twice as likely to carry
C. perfringens type A than MS patients (Figure 23) led to the hypothesis that type
A may also outcompete toxinogenic types B and D for crucial resources in the
human gut. We found that soluble factors from C. perfringens conditioned media
were able to inhibit the growth of a non-isogenic strain (Figure 28). However,
when cultured together, our laboratory type B strain (ATCC 3626) outcompeted
our laboratory type A strain (ATCC 12915) (Figures 29 and 30). Although
seemingly contradictory to our hypothesis of type A dominance, it must be noted
that this type A strain is pathogenic, and secretes enterotoxin (CPE) causing food
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borne diarrhea in humans. Therefore, it is not a human commensal.
Furthermore, this experiment has been conducted between just two of the many
different strains of C. perfringens types A and B that exist in the environment.
This particular result may be restricted to how these two unique strains interact
with each other. The more important point to glean from this experiment is that
C. perfringens secretes molecules that functionally inhibit growth of non-isogenic
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Figure 29. A Competitive Growth Assay Between Type A and Type B.
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type A colonies are large and flat and non-sulfur reducing (clear) on PAB agar.
(Middle) type B colonies are small, raised and sulfur reducing (black) on PAB
agar. (Right) when added in equal concentrations, type B colonies inhibit type A
growth and are the dominant presence on the PAB plate.
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Patient 73F, who was determined to be type B positive three months after
her first clinical episode, became negative for all C. perfringens strains upon a
second PCR stool analysis eight months later during her second visit to the MS
clinic. Repeat MRI showed that she had developed new lesions since her first
visit. While it is not possible to pin point when these new lesions may have
occurred relative to her negative ETX PCR, the finding that she had converted
from CIS to MS without stable detection of C. perfringens type B gives rise to
many questions. 1) Could ETX be an initial trigger that catalyzes the MS disease
process but is not required for propagation of the disease? This model has been
termed, the “hit-and-run” hypothesis. If we suspect that ETX causes the BBB
breakdown and non-immune mediated oligodendrocyte apoptosis found in each
newly forming lesion by Barnett et al. and Adams et al. (Adams RD 1952; Barnett
and Prineas 2004), then the ETX gene and toxin must be present in the MS patient
at the time of relapse. Therefore, the hit-and-run model is not consistent with the
ETX/MS hypothesis.
It is possible that our detection methods may not have been sensitive
enough to detect type B later on in her disease course. Perhaps a
larger/detectable bacterial load is necessary early on in MS to establish persistent
carriage, which is below our detection limits. Alternatively, it is possible that
type B/D carriage is, in fact, transient and we are often exposed to type B/D
spores or vegetative cells, but only a small percentage of individuals possess a
host environment that allows for transient colonization, toxin production and
subsequent neurologic disease.
There is yet one other possibility, which may significantly add to the
complexity of this potential host-pathogen interaction. Could it be possible that
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C. perfringens type B/D is necessary for the introduction the ETX gene to the
human gut early in MS, and that mobilization of the ETX gene via horizontal
gene transfer allows ETX to persist in the host after type B/D has been
evacuated? Interspecies horizontal transfer of the ETX gene would be of
enormous consequence to this study as our culture techniques are aimed at
selectively culturing C. perfringens. Indeed, we could be reducing our ability to
detect the ETX gene in MS patients by precluding the growth of other gut
species. Although interspecies horizontal transfer of C. perfringens mobile
elements is yet to be observed in a laboratory setting, many factors suggest that it
is at least possible. Furthermore, there is evidence that C. perfringens and C.
difficile have transferred genes in the past (Lyras, Storie et al. 1998).
The ETX gene is encoded on two distinct plasmids, a type B and type D
plasmid (Havard, Hunter et al. 1992). These plasmids carry the tcp (transfer
clostridial plasmid) genes, which encode the structural proteins required for
conjugative pilus formation. Not only is ETX on this replicative mobile element,
but it is also flanked by Insertion Sequences (IS), simple transposons, at both the
5’ and 3’ ends. These flanking mobile elements make this entire unit of DNA
(IS1151-ETX-IS406) a composite transposon that is capable of excision and
transposition into a new locus (Figure 31A). Furthermore, it has been shown that
the ETX gene can exist as a conformational intermediate of the transposition
process suggesting that transposition indeed occurs (Sayeed, Li et al. 2007)
(Figure 31B).
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FIG. 7. (A) Arrangement of the etx locus in cpe-negative cpb2-negative type D isolates based on the results shown in Fig. 6. The designations
below the line indicate the primers used to evaluate circular intermediate formation. (B) Map of the circular intermediate based on PCR and
sequencing (not shown). (C) PCR amplification of the circular intermediate. The positions of molecular size markers are indicated on the left, and
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the lanes.
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explain this observed etx plasmid diversity; i.e., nearby IS seunderstand the contributions to virulence and the evolution of
resistance. These mobile elements excise structural
genes, such as toxins and
quences could mobilize etx sequences from one etx plasmid,
these plasmids.
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while IS1151 sequences are located near the !-toxin genes in
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cell
has acquired
(9)inhas
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the evolution
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type E isolates
(3,occur
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has beenthe
suggested
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at least
foroccur
perfringens; e.g., this could help explain why some type D isothe chromosomal cpe gene (6) and !-toxin gene (15), these IS
lates carry a single plasmid with three different toxin genes.
sequences can mobilize the adjacent toxin gene, thereby afIn our etx sequencing study we found that most or all type D
fecting the evolution of virulence of individual C. perfringens
isolates and, by extension, the entire species. In a previous79 isolates have an etx gene sequence that is highly conserved at
the nucleotide level, as well as the amino acid level. Previously,
study the workers identified an IS1151 sequence upstream of
it was shown that the etx gene of one type B isolate encodes an
etx in a few type D isolates (8, 24), but our findings suggest that
!-toxin prototoxin with serine at amino acid residue 321, while
there may be a more complicated relationship between IS1151

the mobile element on a transferred plasmid or circular transposition
intermediate (Puopolo, Klinzing et al. 2007). ETX’s ability to be transposed is
incredibly significant because transfer of an ETX plasmid alone would not be
sufficient for a successful horizontal transfer. Foreign plasmids are often unable
to replicate and are unstable in bacteria of different species, and this is true for C.
perfringens plasmids, as they require the presence of the C. perfringens specific Rep
protein for stability (Bannam, Teng et al. 2006). Therefore, ETX would have to be
excised and transposed into the recipient’s endogenous DNA to replicate and
function. The fact that ETX is part of a composite transposon makes this
possible.
There is another significant hurdle to interspecies horizontal transfer of ETX
that must be addressed. Although the ETX plasmid is conjugative between C.
perfringens strains, there is no evidence that C. perfringens can conjugate with
another species by the normal plasmid mediated conjugative mechanisms.
However, there is evidence that C. perfringens may be capable of horizontal
transfer with C. difficile via an alternate and less well understood conjugative
process. Investigators suspect that horizontal gene transfer has actually occurred
between C. perfringens and C. difficile in the past, most likely via conjugative
transposons. Rood et al. compared chloramphenicol resistance genes and other
mobile elements in C. perfringens and C. difficile. They concluded that these genes
were so similar that horizontal transfer by a conjugative transposon was the most
likely mechanism (Lyras, Storie et al. 1998).
Conjugative transposons differ from regular transposons in that, in addition
to being transposable mobile elements, they also encode their own conjugation
proteins. Importantly, the conjugative pili formed by conjugative transposons
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are promiscuous in their recipient targeting and will frequently conjugate with
bacteria of different species. Additionally, while plasmid conjugative pili are
exclusive for the transfer of the encoding plasmid, transposon conjugative pili
allow the transfer of mobile elements in a non-specific fashion. Moreover,
conjugative transposons have actually been shown to actively mobilize
neighboring mobile elements for interspecies transfer (Salyers, Shoemaker et al.
1995).
Tn916 is a prototypic conjugative transposon that originates from
Enterococcus faecalis and is thought to play a major role in the interspecies
spread of antibiotic resistance genes. Once transposed into another bacterial
species, Tn916 confers the ability to perform promiscuous interspecies
conjugations to the recipient species (Roberts and Mullany 2011). Once the
mating pore is formed, other mobile elements, such as plasmids, are mobilized
and transferred. Haack et al. showed that a Tn916 carrying Bacillus subtilis
transferred its pC194 plasmid to Bacillus thuringiensis via the Tn916 mating pore
(Haack and Andrews 2000). Importantly, Tn916 easily transposes C. perfringens
in a laboratory setting (Awad and Rood 1997), however co-transfer of C.
perfringens plasmids/circular transposition intermediates via the Tn916 mating
pore has not been investigated.
The fact that C. perfringens and E. faecalis share the same habitats (soil and
animal GI tracts) and the ease with which Tn916 transposes C. perfringens
support the idea that such a transposition event may occur in the natural
environment. Although no functional conjugative transposons of C. perfringens
origin have been identified, it is of interest that a defective Tn916-like transposon
has been identified in C. perfringens (strain CW459). Although classified a Tn91681
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Although no functional conjugative transposons have been identified in C.
perfringens, from probing the whole genome sequence of C. perfringens type B
ATCC 3626, we have discovered a previously unidentified conjugative
transposon. This novel C. perfringens conjugative transposon shares an almost
identical modular identity to the prototypic Tn5397 transposon found in C.
difficile str. 630 (Figure 33). However, most of the modular proteins are quite
divergent in their amino acid identity when compared to Tn5397. Surprisingly,
most of these proteins share a high degree of amino acid identity (> 90 identity
for 8/13 proteins) with another unidentified conjugative transposon that is also
found in C. difficile (ATCC 43255 strain) (Table 5). The fact that the C. difficile
proteins are of equal or greater identity than homologues from C. perfringens
type D strain JGS1721, suggests that these homologues are the result of a
conjugative transposition between C. perfringens and C. difficile, rather than
divergent evolution from a common Clostridial ancestor. Perhaps the most
important feature of this novel C. perfringens conjugative transposon is that it
encodes a putative resolvase protein that is homologous to the TndX resolvase
encoded by Tn5397. Resolvase is necessary and sufficient for both DNA excision
and integration. Therefore this novel conjugative transposon may be functional.
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Table 5. A Comparison of Amino Acid Identities Between Conjugative
Transposon Genes in C. perfringens Type B, Type D and C. difficile.
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Future Directions

Identify the ETX pore in MS brain tissue: While suggestive, this preliminary
study fails to prove that exposure to Clostridium perfringens epsilon toxin
triggers the initial demyelinating event in MS. We propose that a definitive
experiment will involve identifying the toxin, in situ, in the MS brain. In pursuit
of this experiment we have generated affinity purified polyclonal antibodies
against ETX, but have found that these antibodies are unable to bind to ETX once
it has made contact with the cell membrane. ETX is pore-forming protein that
attaches to susceptible cells, changes conformation as it inserts into the plasma
membrane, and kills cells by osmotic lysis. Because a significant portion of the
ETX molecule inserts into the membrane, antibody accessibility is likely to be
greatly reduced when ETX is cell bound. Additionally, the conformational
change may also reduce antibody binding by altering the structure of
immunoreactive epitopes.
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Finally, ETX inserts into lipid raft structures, which are densely decorated
with carbohydrates and GPI linked proteins that may mask the ETX pore from
antibody recognition. We will address these experimental hurdles in two ways:

1) Try different methods of antigen retrieval e.g. proteinase K, urea and citrate
treatment of brain sections from ETX treated rodents to determine if these any of
these treatments will unmask immunoreactive epitopes.

2) Design a DNA aptamer that will be small enough to access and specifically
bind to the membrane spanning ETX pore.

A brief review of DNA aptamers and aptamer development: Aptamers are
small oligonucleotides that specifically bind to a wide range of target molecules,
such as drugs, proteins, or other inorganic or organic molecules, with high
affinity and specificity. The concept of aptamers is based on the ability of small
oligonucleotides (typically 80-100mers) to fold into unique three-dimensional
structures that can interact with a specific target with high specificity and affinity
(Mallikaratchy, Liu et al. 2009). As aptamer development is not our expertise, we
will be collaborating with Dr. Probodhika Mallikaratchy of Lehman College. Dr.
Mallikaratchy is an accomplished scientist in the aptamer development field. She
has successfully developed aptamers that recognize protein kinase C-delta5, IgM
heavy chain in Burkitt’s lymphoma cells (Mallikaratchy, Tang et al. 2007), and
the B cell receptor on human leukemia and lymphoma cells (Mallikaratchy,
Ruggiero et al. 2011).
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An ETX pore specific aptamer, will allow us to design and execute
experiments that will definitively address whether ETX is indeed a trigger for
nascent MS lesions. In addition to routine histology, aptamers can also be used in
a clinical setting for both research and therapeutic purposes. For example, during
an MS exacerbation, a radiolabeled aptamer could identify ETX in living patients
via PET imaging. Furthermore, aptamers could be coupled to molecules capable
of capping the ETX pore, thus preventing cell lysis and ameliorating MS
symptoms.
Cell based aptamer selection: We will use MDCK cells, which are known to be
susceptible to ETX, to develop a Flow Cytometry based assay for aptamer
selection. Aptamers that bind to the ETX pore will be subjected to multiple
rounds of enrichment and PCR amplification until highly pore-specific sequences
are identified. Briefly, We will perform a titration of MDCK cells (500,000
cells/ml) with increasing concentrations of ETX and measure propidium iodide
uptake after 1hr of incubation. We will select a concentration that corresponds to
the beginning of the PI uptake plateau. This early plateau concentration will be
used for the remainder of the study to ensure that the entire quantity of toxin
present exists in the heptameric pore conformation. It will be important to avoid
saturating the cells with toxin such that some of the bound ETX remains
monomeric, as we only wish to select aptamers that recognize the ETX pore.
Toxin treated MDCK cells will be incubated with a commercially available DNA
library. Each unique DNA sequence will be flanked by conserved sequences at
both the 5' and 3' ends. These conserved sequences will be used as recognition
sites for PCR primers and subsequent PCR amplification. The DNA oligomers
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will also be fluorescently labeled so that we may visualize aptamer binding.
After the first round of incubation and washing of the cells, heating the sample
will elute the bound DNA sequences. We will cool the eluted DNA, thus
allowing it to regain its original structure, and incubate with non-treated MDCK
cells as a negative selection measure. The unbound sequences (the sequences of
interest) will be isolated and PCR amplified. We will repeat these selection and
amplification steps multiple times until we have generated a pool of oligomers
that probe ETX treated cells exclusively. Finally, we will sequence the evolved
oligomers to determine their primary structures. Each of the above steps is
summarized below in Figures 34 and 35.
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-!!./)!0)11+23435!67869)(!:)1)08%;<!7(;0)::!=)>)1;7)=!?@!8/)!.6<!&(;'7-!A!::BCA
Figure 34. A Schematic of Cell Based Aptamer Selection. The cell-SELEX
aptamer selection process developed by the Tan group. A ssDNA pool is
7;;1!%:!%<0'?68)=!D%8/!86(&)8!0)11:-!AE8)(!D6:/%<&F!8/)!?;'<=!BCA:!6()!)1'8)=!?@!
incubated with target cells. After washing, the bound DNAs are eluted by
/)68%<&!8;!GHIJ-!./)!)1'8)=!BCA:!6()!8/)<!%<0'?68)=!D%8/!<)&68%>)!0)11:!E;(!0;'<8)
heating to 95°C. The eluted DNAs are then incubated with negative cells for
:)1)08%;<-!AE8)(!0)<8(%E'&68%;<F!8/)!:'7)(<686<8!%:!0;11)08)=!6<=!8/)!:)1)08)=!BCA!%:
counter-selection. After centrifugation, the supernatant is collected and the
6971%E%)=!?@!KJL-!./)!KJL!7(;='08:!6()!:)76(68)=!%<8;!::BCA!E;(!8/)!<)M8!(;'<=!
selected DNA is amplified by PCR. The PCR products are separated into ssDNA
:)1)08%;<-!$%<611@!8/)!)<(%0/)=!1%?(6(@!D%8/!67869)(!:)N')<0):!%:!01;<)=!6<=!
for the next round of selection. FinallyOH!
the enriched library with aptamer
:)N')<0)=!8;!;?86%<!67869)(!06<=%=68):-!
sequences is cloned and sequenced to obtain aptamer candidates. (Shangguan, Li
et al. 2006)

b

89

:)1)08%;<-!$%<611@!8/)!)<(%0/)=!1%?(6(@!D%8/!67869)(!:)N')<0):!%:!01;<)=!6<=!
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Figure 35. FACS Analysis of Aptamer Enrichment. (a) The green curve
0'(>)!()7():)<8:!8/)!?60R&(;'<=!?%<=%<&!;E!8/)!:86(8%<&!BCA!1%?(6(@-!A<!%<0()6:)
represents the background binding of the starting DNA library. An increase in
E1';():0)<0)!%<8)<:%8@!D%8/!8/)!<'9?)(!;E!0@01):!%:!%<=%068%>)!;E!)<(%0/9)<8!;E!8/)
fluorescence intensity with the number of cycles is indicative of enrichment of
6EE%<%8@!8;D6(=:!8/)!86(&)8!0)11:-!P?Q!4%881)!0/6<&)!%:!;?:)(>)=!E;(!8/)!0;<8(;1!0)11:the affinity towards the target cells. (b) Little change is observed for the control
P$;(!%<E;(968%;<!;<!E1;D!0@8;9)8(@F!:))!A77)<=%M!AQ!
cells. (Shangguan, Li et al. 2006)

A detailed microbiome assessment: "#!
We wish to 1) validate our preliminary
observation with a larger cohort by expanding the numbers of patients and
healthy controls analyzed for C. perfringens toxinotypes. 2) specifically
interrogate distinct body habitats for C. perfringens toxinotypes, which have not
previously been performed in MS or healthy controls using optimal culture
techniques. 3) study a cohort of patients and controls longitudinally over a twoyear period, and thus define variation in C. perfringens toxinotype abundance
over time in individual patients. 4) compare the sensitivities of C. perfringens
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specific culture methods to that of high-throughput technologies for
identification of C. perfringens. 5) perform high throughput sequencing of 16S
rRNA genes and characterize/compare microbiomes to identify the microbial
communities that may be specific for MS patients and determine environmental
pressures that may shape susceptibility to C. perfringens types B and D
colonization.

Create a new animal model for MS: As previously mentioned, no animal model
currently exists that accurately recapitulates the tissue damage and
symptomatology of MS. ETX provides the unique opportunity to induce spastic
paralysis, Dawson’s fingers-like periventricular lesions, breakdown of the bloodretinal barrier in addition to the blood-brain barrier, and perhaps most
importantly, cause damage to oligodendrocytes in the absence of an immune
infiltrate; similar to what has been observed in newly forming MS lesions. We
wish to model each of these characteristics in vivo, ex vivo and in vitro.
Furthermore, we wish to supplement our in vivo histological analyses with small
rodent MRI imaging. This will be particularly useful in assessing ETX’s ability to
recapitulate Dawson’s fingers.

Address whether interspecies ETX gene can transfer occur: Interspecies
horizontal gene transfer is frequently observed and has been well studied for
antibiotic resistance genes. However, less attention has been paid to bacterial
toxins despite the fact that toxins are often carried on the same types of mobile
genetic elements. Evidence for interspecies toxin transfer would have an
enormous impact on how we proceed with this study. It would change our
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experimental design and may open new avenues for future research. With this
in mind, we wish to determine whether the introduction of a conjugative
plasmid such as Tn916, derived from Enterococcus faecalis, can facilitate
interspecies mating and transposition of the ETX gene from C. perfringens to a
distantly related organism. It may also be fruitful to isolate commensal C.
perfringens type A strains from MS patients and controls, and determine their
relative abilities to acquire the ETX gene through conjugation with a type B or D
toxinotype. Perhaps commensal type A strains from MS patients more readily
acquire the ETX gene, thus obviating the need for true colonization by a
toxinogenic type B or D strain.
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CHAPTER 3

A Review of Protein Toxins, ETX and The Elusive ETX Receptor

Toxins are any poisonous substance produced by a living organism that is
capable of causing disease or death in other organisms (Elisabete Valério 2010).
These molecules come in many different flavors; proteins, small molecules,
alkaloids etc. and may disrupt cellular function in a myriad of ways. Indeed, the
most toxic molecules known to man are bacterial toxins derived from the
Clostridium genus; Clostridium botulinum, tentanus and perfringens epsilon toxins
being the three most toxic molecules in descending order. It is likely that these
Clostridial toxins display such devastating toxicities because they each affect the
central nervous system (CNS), which is critically important for sustaining life.
Thus, it is important to note that a toxin’s potency is not only dependent on its
mechanism of action, but also its target tissue, and the importance of that target
tissue to the organism’s viability.
Although evolved to harm other organisms and to confer an evolutionary
advantage over competitors, studying the mechanisms by which toxins work has
already yielded therapeutic dividends; perhaps the best example being the use of
botox to treat ailments of muscle spasticity (Brin 2009). Further studies are
currently underway, exploring the potential use of bacterial toxins to selectively
kill cells (Walther, Petkov et al. 2011). The success of these emerging
technologies rests not on how the toxin affects the target cell, but more so on how
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the toxin initiates contact with its target. Indeed, the specificity of bacterial
toxins may prove to be their greatest benefit to medicine.
After binding to the target cell receptor, toxins usually derail cellular
function in one of six ways (Elisabete Valério 2010):
Membrane permeabilization: These toxins start binding to the membrane in their
monomeric form. Afterwards, self-oligomerization occurs resulting in the
formation of pores that are permeable to ions and small metabolites. Ultimately,
this leads to membrane disruption, membrane permeability and osmotic lysis of
the cell (Zitzer 1997).

Toxins affecting membrane trafficking: Some toxins can interfere with several
components of vesicle-associated membrane protein system, altering the
trafficking of molecules like neurotransmitters across the membrane e.g.,
botulinum toxin. (Martinez-Arca 2000; Chen 2009).

Toxins affecting signal transduction: There are toxins that target the intestinal
epithelial cells where, after a complex series of events, they activate adenylate
cyclase, interfering with signal transduction e.g., cholera toxin (Lencer 1995).
Other natural toxins act by modifying key functions of the phosphorylationbased signaling machinery, thus affecting the signal transduction pathways e.g.,
microcystins (Sivonen 1999).

Toxins affecting protein synthesis: This group of toxins can present more than one
mechanism to inhibit protein synthesis. Two examples are the cleavage of several
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nucleobases from the 28S rRNA e.g., Shiga toxins (Cherla 2006) or the
inactivation of elongation factor 2 (eEF-2) by transferring the adenosine
diphosphate ribose moiety (ADP-ribose) of NAD to eEF-2 e.g., Pseudomonas
exotoxin A (Menestrina 1991).

Cytoskeleton-affecting toxins: These toxins can induce structural changes in the
cytoskeleton and consequently inhibit its functions. Cytoskeleton modifications
include the disaggregation of actin microfilaments e.g., Toxin B from Clostridium
difficile (Pothoulakis 1991) or the induction of the formation of giant
multinucleated cells, leading to changes in actin and tubulin organization e.g.,
cytotoxic necrotizing factor of Escherichia coli (Fiorentini 1988).

Voltage-gated ions channels blockers: These toxins have the ability to interact with
the specific receptors associated with neurotransmitter receptors, or with
voltage-sensitive ion channels, therefore inhibiting the nervous signaling e.g.,
saxitoxin, kalkitoxin and jamaicamides (Wang 2008; Aráoz 2010).

Despite the great diversity of toxic mechanism, at least a third of the more
than 300 protein toxins characterized to date damage cells by pore formation and
membrane permeabilization (Alouf 2001). These pore forming proteins often
share similarities in their membrane spanning domains and mechanisms of
oligomerization. However, they are able to target individually specific tissues
due to unique receptor binding domains.
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Pore Forming Toxins

The pore-forming toxin has the unique ability to exist as either a
hydrophilic solute or a hydrophobic, membrane-spanning pore depending on its
surrounding environment. Once released into the host, the toxin must circulate
in solution to find its target cell/tissue; this requires a soluble existence.
However, once bound to its cellular receptor, the toxin must develop the ability
to wedge itself into the lipid bilayer to form a channel; this requires a
conformational change that either exposes buried hydrophobic surfaces or that
oligomerizes the molecule such that a hydrophobic surface is formed
cooperatively. These two distinct mechanisms of toxic pore formation have
arisen in many different organisms, prokaryote and eukaryote alike, by
convergent evolution. Below we will explore how each of these strategies work
on a mechanistic level:
α Pore Formers: α-Pore Forming Toxins (α-PTFs) contain stretches of
hydrophobicity that are predicted to be α helical (Figure 36) that can span the
lipid bilayer resulting in a pore (Iacovache, van der Goot et al. 2008). These long
hydrophobic stretches must be protected such that the molecule does not
aggregate and precipitate before it reaches its cellular target. To avoid such an
occurrence, some α-PTF require a change in the microenvironment, such as pH,
which can destabilize the molecule and expose its hydrophobic regions e.g.
colicin from E. coli. Diphtheria toxin, Cry δ-endotoxins produced from Bacillus
thuringiensis and Pseudomonas aeruginosa exotoxin A are some other exotoxins
that form pores that employ hydrophobic α helices (Parker 2010).
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Figure 36. Ribbon Images of α-PFTs. The regions thought to form the
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are structurally diverse they tend to possess amphipathic structures, a property which seems
important for membrane interaction. Despite much
work on these deceptively simple systems
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their mechanism of pore formation remains an area of controversy. One of the classical examples
of a pore-forming peptide is alamethicin, an alpha-helical peptide that forms clusters of helices
19

β Pore Formers: The majority of bacterial PFTs known to date are β-PTFs.
(Iacovache, van der Goot et al. 2008). β-PTFs are predicted to insert into
membranes to form β-barrels. β-PTFs are released as soluble monomers or
dimers that oligomerize before forming active pores. The final insertion step
often requires significant protein refolding, so that subunits can donate β-strands
to form a transmembrane β-barrel (Tilley and Saibil 2006). Unlike α-PTFs, there
are no long stretches of hydrophobicity. Instead, β-PTF monomers each contain
a β hairpin consisting of alternating hydrophobic and hydrophilic residues so
that when assembled in the membrane, the hydrophilic residues form the lumen
of the pore whereas the hydrophobic residues interact with the membrane core
(Parker 2010). The lack of long hydrophobic regions helps avoid precipitation
but as an additional regulatory step, β-PTFs are secreted as protoxins, e.g. ETX
prototoxin, and must be enzymatically activated for oligomerization to occur
4
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(Parker and Feil 2005). Figure 37 illustrates the ribbon of β-PTFs.

Figure 37. Ribbon Images of
β-PFTs. The regions thought
to form the transmembrane
stretches are highlighted in
dark shade. The archetypical
toxins of the family are
shown in the first row.
(Parker 2010)
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The Aerolysin Family of β Pore Formers

C. perfringens ETX is a member of the aerolysin family of β-PTFs, which
also consists of aerolysin (Aeromonas hydrophila), α-toxin (Clostridium septicum),
Enterolobin (Enterolobium contortisiliquum, a Brazilian tree), LSL (Laetiporus
sulphureus, a mushroom), Mtx2/Mtx 3 (Bacillus sphaericus), Hydralysins
(Chlorohydra viridis, an aquatic Cnidarian) and parasporin-2 (Bacillus
thuringiensis). Despite the fact that these PFT producers originate from diverse
kingdoms represented by plants, fungi and bacteria, most of the PFTs share
remarkable sequence identity with aerolysin. Contrastingly, ETX and
parasporin-2 share very little sequence identity with aerolysin, 13.9% and 25.7%
respectively, but are still classified in the aerolysin family because of structural
similarities within their domain structure (Knapp 2010). As the prototypic
member, aerolysin has been the best characterized of these toxins.
Members of the aerolysin-like toxin family use amphipathic β-hairpins for
membrane insertion and are therefore rich in β-sheets. Although β-PFTs share a
common mode of pore formation, several types can be distinguished according
to their individual receptors, number of monomers forming oligomers, pore size,
and functionality. Like other β-PFTs, aerolysin-like toxins bind to a cell-surface
receptor, oligomerize, and generate β-hairpins from 6 to 7 individual monomers
to form the pore (Table 6) (Knapp 2010).
Aerolysin-like toxins are secreted as protoxins, requiring enzymatic
activation. They bind to high affinity receptors located in lipid rafts, e.g. GPIlinked proteins for aerolysin. The spatial concentration of these receptors within
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the lipid raft is thought to aid in concentrating the toxin such that it can
oligomerize and cooperatively form a hydrophobic surface that can insert into
the membrane. Activated monomers assemble into heptamers (Figure 38) as well
as form channels through insertion into lipid bilayers, as observed indirectly by
electron microscopy since only the mushroom cap and not the transmembrane
region is visible (Wilmsen, Leonard et al. 1992). Heptamers inserted into the
membrane form voltage-dependent, anion selective channels with a single
channel conductance of about 70 pS in 0.1 M KCl which corresponds to a pore
diameter of at least 7 Angstroms (Knapp 2010).
As a consequence of anion-selective transmembrane channels being
formed, a cell can readily lose ions, water, and small molecules (i.e. sugars,
amino acids, nucleic acids) that do not include proteins (Chakraborty, Schmid et
al. 1990; Abrami, Fivaz et al. 1998). Besides breakdown of the Na+/K+ gradient,
an influx of Ca+2 can be observed in cells, which seemingly mediates cell
signaling (Krause, Fivaz et al. 1998). Loss of K+ facilitates formation and
activation of the inflammasome, cytoplasmic multiprotein complexes harboring
Nod-like receptors such as IPAF and NALP3, as well as caspase-1 (Abrami, Fivaz
et al. 1998). Finally, via caspase-1, the K+ efflux mobilizes Sterol Regulatory
Element Binding Protein (SREBP)-1 and -2. Both proteins are involved in the
biogenesis of membranes and their activation enhances cell survival (Gurcel,
Abrami et al. 2006). Caspase-1 is also responsible for the processing and
activation of cytokines IL-1β and IL-18 (Krause, Fivaz et al. 1998), which are also
observed during aerolysin intoxication.
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Table
6. The
Characteristics
Toxin
Family
Members.
The Aerolysin-Like
ToxinMain
Family of Cytolytic,
Pore-Forming Toxinsof Aerolysin-Like The
Open Toxinology
Journal,
2010, Volume 3

55

(Knapp
2010)
Table 1. Main
Characteristics of Aerolysin-like Toxin Family Members
SepticumAerolysin
Enterolobin
-Toxin
(Enterolobium
(Aeromonas (Clostridium
Contortisiliquum)
species)
Septicum)

Parasporin-2

Epsilon-Toxin
Type B and D
(Clostridium
Perfringens)

LSL
(Laetiporus
Sulphureus)

MTXs
(Mtx2/Mtx
3) Bacillus
Sphaericus

Hydralysins
(Chlorohydra
Viridis)

Bacillus
Thuringiensis

Size in kDA:
52

47.5

55

32.5

35

31.8/35.8

27

37

Propeptide:

yes, Nterminal

yes, Cterminal

unknown

yes, N- and Cterminal

unknown

possibly

unknown

Yes, N- and
C-terminal

Pore formation:

yes

yes

possibly

yes

possibly

possibly

yes

possibly

Oligomerization
(number of
monomers):

7

6,7

unknown

7

4,6

unknown

possibly

(monomer
unprocessed)

unknown

Channel
conductance G
[pS]:
0.1 M KCl

72

175

n.m

60

n.m

n.m

n.m

0.3 M "

220

450

n.m

160

n.m

n.m

n.m

n.m

1M"

650

1250

n.m

550

n.m

n.m

n.m

n.m

3M"

1700

3750

n.m

1700

n.m

n.m

n.m

n.m

0.21 (-24
mV)

0.38 (-14
mV)

anion
selective

anion
selective

n.m

n.m

n.m

n.m

0.7 nm

1.3-1.6 nm

GPIanchored
proteins

GPIanchored
proteins,
including
human
folate
receptor
(hFR), Thy1 (CD90),
SAG family

Pcation/Panion:

Pore size:

Receptor

Target cells

GPIanchored
protein
expressing
cells

GPIanchored
protein
expressing
cells

n.m

0.3 (-19 mV)
anion selective

n.m

unknown

1 nm

>3.8 nm

unknown

1.2 nm

unknown

unknown

membrane
protein, not GPIanchored

unknown,
contains Nacetyllactosami
ne
glycoconjugate
s

unknown

unknown

unknown

arthropod and
mammalian cells

only a few cell
lines including
kidney cells
(MDCK,
mpkCCDC14,
human renal
leiomyoblastoma,
and G-402 cells)
and glutamatergic
neurons

n. m. Means not Measured.
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unknown

mainly
insect cells,
larvae of the arthropod and
eukaryotic
genus
cells
Culex,
Aedes, and
Anopheles

Liver and
colon cancer
cells and cell
lines (HepG2,
CACO-2) also
human
leukemia Tcell lines
(Molt-4,
Jurkat, Hl-60)
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Fig. 14. The aerolysin heptamer modelled from electron microscopy images and the crystal structure of the watersoluble
dimer 38.
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Similarities to aerolysin: Although not sharing a high degree sequence identity
(13.9%) with aerolysin, the two molecules are organized in much the same way
structurally (Figure 39). The majority of these two molecules is comprised of
beta sheets, with an N terminal domain that is alpha helical. This helical domain,
domain I in ETX and domain II in aerolysin, is the putative binding domain as it
is rich in aromatic residues, which have been shown to be important for receptor
binding in both molecules. Domain II of aerolysin is thought to be important for
interacting with GPI anchors (MacKenzie, Hirama et al. 1999). There is a cluster
of aromatic residues in this region, which is observed for other sugar-binding
proteins. A similar region with a cluster of aromatic residues (Tyr49, Tyr43,
Tyr42, Tyr209 and Phe212) is present in domain I of ETX, along with the only
tryptophan, which has been previously implicated in receptor binding
(Nagahama and Sakurai 1992). Interestingly, mutation of each of the above ETX
tyrosine residues (Y to E) significantly impairs receptor binding (Ivie and
McClain 2012). Both molecules form a heptameric, anion selective pore,
oligomerization seemingly inhibited by the C terminus of the precursor
molecule. It is likely that the C terminus of each protein sterically hinders
oligomerization of both toxins and their removal likely reveals residues of
importance for oligomerization (Cole, Gibert et al. 2004).
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glycosylphosphatidylinositol (GPI)-anchored proteins; there is limited
evidence of ETX interacting with sugars10.
Despite the similarities, the toxins differ in their target cell specificities and toxicities. Aerolysin has a lethal dose in mice of 10 µg kg–1
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Differences with aerolysin: While aerolysin circulates as a dimer in solution,
ETX exists as monomer. Furthermore, furin activation of aerolysin occurs after
the molecule has made contact with the cell membrane. In contrast, ETX is
activated in the lumen of the gut by trypsin, chymotrypsin or Clostridium
lambda toxin before reaching target cells such as brain endothelium. Aerolysin
causes apoptosis as does ETX, however, ETX can also induce necrosis. Most
importantly, unlike aerolysin, ETX fails to bind to GPI-liked proteins in lipid
rafts and is thus non-hemolytic. Although the putative ETX receptor has been
shown to localize to lipid rafts, its identity remains unknown.

Another important difference with aerolysin is ETX’s ability to form a
prepore intermediate before membrane insertion. In this way, ETX is the rule
while aerolysin is the exception, as most β-PTFs form prepores (Parker 2010). The
prepore comprises a ring of subunits on the surface of the membrane that
contains largely unperturbed monomers. By contrast, the subunits in the pore
have undergone a striking reorganization, resulting in a structure with several
unusual features, including a hollow rim, vertical β-strands and a locally
distorted lipid bilayer (Bayley, Jayasinghe et al. 2005). Robertson et al. found
that at 4 degrees C, treating MDCK cells with ETX led to the formation of a nontoxic heptameric prepore. If the treated cells were then moved to 37C, the
prepore was able to insert into the membrane and lyse the cells (Figure 40). To
evince membrane insertion, Robertson treated both the 4C and 37C preparations
with pronase, and only observed pronase degradation of the ETX pore in the 4C
circumstance. The investigators concluded that at 4C, pronase can access the
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ETX prepore, however, pronase cannot access the pore once it has inserted into
the membrane at 37C (Robertson, Li et al. 2011). Although low temperatures can
inhibit membrane insertion of the ETX prepore, it is interesting that the toxinreceptor interaction is unaffected.

C. perfringens Epsilon Toxin Has a Prepore Stage

Figure 9. Updated Model for ETX action in MDCK II cells. Mode of action begins with activated ETX binding to proteinacous membrane
receptor. Bound ETX then oligomerizes to form a heptameric prepore on the membrane surface. At 4uC, the process stops here, but at 37uC the
prepore intermediate inserts into the membrane to complete pore formation.
doi:10.1371/journal.pone.0022053.g009

Figure 40. A Schematic of ETX Pore Formation. Mode of action begins with

activated ETX binding to proteinacious membrane receptor. Bound ETX then

oligomerizes to form a heptameric prepore on the membrane surface. At 4C, the

supporting the trapping of ETX in a prepore stage at 4uC, these
and influx of other ions such as calcium. These pore-induced
differences in SDS stability of ETX complexes at 4uC vs. 37uC
permeability effects cause or contribute to ETX-induced cell
process stops here, but at 37C the prepore intermediate
inserts into the
could reflect temperature-related conformational differences due
death.
to the presence of ETX complex in a prepore vs. active pore
membrane to complete pore formation. (Robertson, Li et al. 2011)
state.
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Knapp et al. have demonstrated that an amino acid stretch in domain II of
ETX, position 151-180, is critical for channel formation. Mutations along this
region can impair pore formation and even change pore characteristics from
anion selectivity to cation selectivity (Knapp, Maier et al. 2009). Surprisingly,
this change in ion selectivity has minimal impact on ATP depletion and ETX
toxicity, suggesting that the influx of Na+ and Ca2+ are not significantly involved
in ETX mediated cell death.
It seems that ETX toxicity may not be entirely due to pore formation and
reduction in membrane potential. Chassin et al. have demonstrated that
disruption of lipid rafts with methyl-β-cyclodextrin inhibits ETX heptamerization
and pore formation, but cellular ATP depletion still occurs. There is an
apopotosis-like signaling cascade that involves stimulation of the AMP-activated
protein kinase, induction of mitochondrial membrane permeabilization and
mitochondrial nuclear translocation of apoptosis-inducing factor (AIF), which is
a potent caspase-independent cell death effector. ETX can also lead to cellular
necrosis evidenced by nuclear shrinkage without DNA fragmentation (Chassin,
Bens et al. 2007).
Contrastingly, Fennessey et al. present a model of ATP depletion that
argues for the importance of pore formation. By their model, ETX pores allow
the escape of essential coenzymes that are essential for ATP production (CoA,
and its precursor, pantothenate, NAD+ and NADH, and carnitine). This leads to
a dissipation of mitochondrial membrane potential and release of mitochondrial
apoptosis mediators such as AIF. The same mechanism seems to be true for
aerolysin mediated apoptosis (Fennessey, Ivie et al. 2012).
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Efforts have been made to generate non-toxic ETX mutants, which can
serve as antigens for vaccination or dominant negatives. Mutations of key amino
acids have been identified. Oyston et al. showed that mutating histidine 106 to
proline, complete abolishes ETX toxicity without destabilizing the molecule
(Oyston, Payne et al. 1998). The exact mechanism by which this mutation
renders ETX non-toxic remains unknown. These investigators hope to develop
the H106P mutant as a cost effective recombinant vaccine.
Dominant negatives have also been explored. ETX-I51C/A114C and ETXV56C/F118C have been identified as two mutants that lack observable
cytotoxicity. The ability to reconstitute the cytotoxic activity of the ETXI51C/A114C and ETX-V56C/F118C mutant proteins by treatment with DTT
suggests that the cysteine substitutions per se are not responsible for the lack of
cytotoxicity. Rather, it is likely that disulfide bonds formed between the
introduced cysteines are responsible for the lack of cytotoxicity. These results are
consistent with the hypothesis that the membrane insertion domain of the ETX
undergoes a structural transition in the process of intoxicating host cells.
Furthermore, insertion of a disulfide bond between an amino acid within the
membrane insertion domain and an amino acid in the protein backbone blocks
the structural transition required for ETX mediated cytotoxicity (Pelish and
McClain 2009).
Finally, neutralizing antibodies have also been developed, identifying a
region of ETX that seems to be critical for membrane insertion. Both 4D7 and
5B7 monoclonals target the amino acid stretch 134 to 145 (SFANTNTNTNSK)
(McClain and Cover 2007). These amino acids map to the β hairpin, amphipathic
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loop of ETX (Figure 41) that has been proposed to oligomerize and insert into the
cell membrane.
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lysin and the homologous alpha-toxin of Clostridium septicum,

The Elusive ETX Receptor

Despite its importance, the mammalian receptor for ETX remains
unknown. However, it has been shown that ETX targets a remarkably small
number of tissues and cell types; namely renal cell lines (canine MDCK, human
ACHN, human G-402 and murine mpkCCDc14 cells), brain endothelial cells, the
distal tubule of the kidney/renal collecting ducts, granule cells of the cerebellum,
CNS myelin and PNS myelin (Popoff 2011) and peritoneal macrophages
harvested from guinea pigs and rabbits (Buxton 1978). In addition to being
expressed by an exclusive list of cell types, the ETX receptor has also been shown
to localize to Detergent Resistant Membranes or lipid rafts (Miyata 2002).
Although causing cell death in the majority of cell types studied, in some
instances, there seems to be greater nuance to the target cell-ETX interaction. In
cerebellar granule cells, ETX exposure does not lead to cell death, but rather
results in glutamate release. Using both primary cell culture and cerebellar slice
culture methods, Lonchamp et al. found that ETX bound to the soma of the
cerebellar granule cells and depolarized these neurons. The drop in membrane
potential, presumably by pore formation, triggered Ca2+ influx and glutamatergic
synaptic release (Lonchamp, Dupont et al. 2010). Interestingly, the authors failed
to observe cytotoxicity in the cerebellar slices, but observed late/delayed
cytotoxicity in granule cell primary cultures.
Other nuanced ETX interactions become clear when studying its effects
on macrophages and lymphocytes from different species. Buxton harvested
immune cells from mice, rabbits, guinea pigs and sheep and observed
heterogeneous ETX cytotoxicity (Table 7).
110

OF C. WELCHII
EPSILON
O N CELLS
301
Table 7. TheEFFECTS
In Vitro Effects
of ETX on
Guinea TOXIN
Pig, Mouse,
Rabbit and Sheep

TABLE
The in-vitro efect of epsilon toxin on guinea-pig, mouse, rabbit and sheep cells

Cells. (Buxton 1978)

Animal
species

Guinea pig

Mouse

Rabbit
Sheep

Type of cell

Number
of
animals

i

Peritoneal macrophages
Peritoneal macrophages
Peritoneal macro phages
Peritoneal macrophages
Peritoneal macrophages
Pulmonary alveolar macrophages
Lymphocytes
Iiympbocytes

Incubation
time
(min.)

5
5
5
5
5
2
1
1

30
30
30
30
30
180
30
60

2
3
1
1

Peritoneal macro phages
Peritoneal macrophages
Peritoneal macrophages
Peritoneal macrophages
Pulmonary alveolar macrophages

2
2
3

1

Lymphocytes

{

Peritoneal macrophages
{Peritoneal macrophages
Lan Scliultz ascites-tumour cells
Lan Schultz ascites-tumour cells

Toxin

Percentage
of cells
(cLgper ml)
killed
0.001
0.01
0.1
1.0
10.0

20

3
4
5
33
79.5

0
0

20

20

0

30
165
150
180

20
20
20
20

0
0

30
60

90

2

150
150

20
20
20
20
20

11.
26.
40.
45.5
0

1

30

20

0

0
0

cytoplasmic membranes appeared " blistered " and were sometimes discontinuous (fig. 2). Iqtracytoplasmic organelles were almost completely lost.
Cells treated by the immunoperoxidase method after exposure to formalinised epsilon prototoxin showed clearly defined brown lines of horseradishThere is a surprising intraspecies heterogeneity in ETX toxicity as
peroxidase reaction product closely adherent to their outer margin (fig. 3).
These deposits
were not from
seen different
in duplicate
control sections
(fig. species
4).
peritoneal
macrophages
individuals
of the same
show
of toxin on
cells other than
different degrees of Eflect
susceptibility.
Furthermore,
onlyGPPM
rabbit and guinea pig
The results are summarised in the table. Toxin at concentrations as high as

peritoneal
are affected,
to interspecies
20 pg per macrophages
ml had no effect
on any pointing
preparation
except the differences.
rabbit peritoneal

macrophages which, when compared with the GPPM preparations, were not

Finally,
the
effect seemsHigher
to be restricted
to peritoneal
asperiods
pulmonary
nearly as
susceptible.
concentrations
of toxinmacrophages
and prolonged
of

incubation were necessary to produce a mortality of over 40%.

macrophages and lymphocytes seem to remain unaffected.

DISCUSSION
It has been shown that epsilon toxin readily kills guinea-pig peritoneal
in vitromembranes
but that guinea-pig
pulmonarymacrophages
(GPPM)
localize
to detergent
resistant
or lipid lymphocytes
rafts. Miyataand
et al.
showed
alveolar macrophages remain viable after similar treatment. This difference in
that
radiolabeled
ETX associated
thatawere
isolated
fromencounMDCK
susceptibility
between
cells of thewith
samelipid
typerafts
within
species
was also
tered in the rabbit, although rabbit peritoneal macrophages were much less
susceptible than those of the guinea-pig.
Guinea-pig peritoneal macrophages were shown to bind formalinised epsilon
prototoxin on their outer surfaces and as it has been shown that this antigen
Once ETX encounters a susceptible cell type, it has been reported to
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membranes using cold Triton 100X extraction and sucrose gradient separation
(Miyata 2002).
From enzymatic digestion studies of ETX susceptible membranes,
investigators have found that ETX binding is sensitive to pronase, sialidase and
is completely abolished by lipase (Dorca-Arévalo, Soler-Jover et al. 2008),
suggesting that the ETX receptor maybe a glycoprotein residing in a lipid
environment that facilitates binding. An alternate and unexplored hypothesis is
that the receptor may not be a glycoprotein, but rather an unmodified protein
that simply resides in a carbohydrate and lipid rich environment. The lipid raft
environment contains a high density of glycosphingolipids and fits this
description.
Dorca-Are ́valo et al. demonstrate the importance of carbohydrate
residues in ETX binding by showing that beta-elimination of O-liked
carbohydrate groups abolishes ETX binding while removal of N-linked sugars
with N-glycosidase F has no effect. They also show that pronase and detergent
treatments also mitigate binding, leading to the conclusion that the receptor may
be an O-linked glycoprotein residing in a lipid environment that is conducive to
ETX binding (Dorca-Arevalo, Martin-Satue et al. 2012). One oversight in this
hypothesis is that the carbohydrate moieties of lipid raft glycosphingolipids are
also O-linked. Therefore beta-elimination may not be acting on a glycoprotein,
but may instead target glycosphingolipids that are crucial for ETX to bind to its
unmodified protein receptor that merely sits in the lipid raft.
Mutation of the putative ETX binding domain has revealed that aromatic
amino acids are critical for binding. This has reinforced the idea that ETX, at
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least in part, binds to sugar moieties because similar interactions have been
observed for aerolysin and other sugar binding proteins (Cole, Gibert et al. 2004).
Ivie et al. generated four ETX mutants, ETX-Y29E, ETX-Y30, ETX-Y36E and ETXY196E, all of which showed defects in ETX binding (Ivie and McClain 2012).
To date, only one molecule has been proposed to directly interact with
ETX. Bruggemann et al. used gene-trap mutagenesis to identify mammalian
proteins that modulate ETX toxicity. They identified, hepatitis A virus cellular
receptor 1 (HAVCR1) and showed that ETX can bind to HAVCR1 by Western
blot. However, when transfected into HEK293 cells, an ETX resistant cell line,
HAVCR1 failed to induce ETX binding and/or confer ETX susceptibility
(Bruggemann, Ivie et al. 2011). Although a provocative candidate receptor, this
lack in vivo functionality suggests that a better candidate receptor may exist.
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CHAPTER 4

Is Myelin and Lymphocyte Protein (MAL) a Functional ETX Receptor?

As a preliminary step toward identifying a candidate ETX receptor, we
searched the literature for lipid raft associated proteins that are expressed by
multiple ETX susceptible cell types and tissues e.g. oligodendrocytes and distal
tubule of the kidney. Surprisingly, only one protein fit each of these
specifications, Myelin and Lymphocyte protein (MAL). Because ETX targets the
BBB and spares peripheral vasculature, we hypothesized that MAL may be
enriched at the BBB. To test this idea we contacted Dr. Richard Daneman, a BBB
investigator at UCSF. Dr. Daneman has performed a transcriptome comparison
of BBB endothelial cells vs. lung and liver endothelial cells to determine BBB
specific gene expression. Furthermore, upon our request, Dr. Daneman was able
to select genes shared by BBB endothelium and myelin, as he was a member of
Ben Barres’ lab (Stanford University), which has performed similar transcriptome
comparisons for glial cell (astrocyte and oligodendrocyte) specific gene
expression. Below are the BBB specific genes that are also shared by the
oligodendrocyte-myelin unit:
1. Mfsd2
2. Ddc
3. Prom1
4. MAL
5. Elovl7
6. Bche
7. Slc1a1
8. Dixdc1
9. Gstm7
10. Apod
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11. Chn2
12. Mpzl1
13. Tbc1d14
14. Osbpl1a
15. Cobll1
16. RGC-32h
17. Acsl3
18. Cdc216
19. 5133401H06Rik
Indeed, MAL was on this short list of genes and was one of the few hits
that trafficked to the membrane, which would be necessary to interact with
ETX. Dr. Daneman also provided the ratios of BBB MAL expression to both
lung and liver endothelial expression; 50x Brain/Lung and 7x Brain/Liver
(personal communication).

A review of Myelin and Lymphocyte Protein (MAL)

MAL is a highly hydrophobic, 17kDa, tetraspan, membrane proteolipid that
is expressed by myelin, MDCK cells, and the distal tubule of the kidney all of
which have been shown to bind ETX. MAL is also found in human T
lymphocytes, for which no association with ETX has ever been demonstrated,
and a variety of epithelial cell types. This molecule contains two extracellular
loops (ECLs), one of which has a high density of aromatic amino acid residues
(Figure 42) much like the putative ETX binding domain. It is conceivable that an
aromatic-aromatic pi stacking or T stacking interaction may facilitate a MAL-ETX
binding event.
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peripheral blood T cells, thymocytes and various T cell leukemia cell lines such
as Jurkat, HPB-ALL and peer cell lines express MAL (Rancano, Rubio et al. 1994;
Millan and Alonso 1998). He also showed that MAL could be expressed as four
different isoforms, representing every combinatorial scenario for the presence
and/or absence of ECLs 1 and 2 (Figure 43).

Figure 43. The Proposed Structure of the MAL Isoforms. Please note that the
most N-terminal region (diagonal hash marks) is thought to reside completely
within the plasma membrane and is not an ECL. (Rancano, Rubio et al. 1994)
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Interestingly, mutation of the ECL2 results in MAL mislocalization within
the IS, from the central IS to the peripheral IS. MAL mislocalization results in
aberrant targeting of virtually all IS adapter proteins from the central IS to the
peripheral IS (Figure 44). However, the T cell receptor (TCR) is still able to
correctly traffic to the central IS (Anton, Andres-Delgado et al. 2011).
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The authors conclude that this mistargeting phenotype at the IS may, in
part, be due to MAL’s ability to maintain highly ordered membranes, or lipid
rafts (Anton, Andres-Delgado et al. 2011). Indeed, MAL has been shown to be an
important player in the formation and maintenance of lipid rafts in T cells,
oligodendrocytes and various epithelial cell types.
Robust T cell MAL expression may be limited to humans however, as no
expression of MAL transcript was found in the rat thymus and only low levels
were detected in the rat spleen. In line with these findings, Northern blots and in
situ hybridization showed barely detectable MAL mRNA levels in the rat spleen,
while protein was beyond detectable limits (Frank, van der Haar et al. 1998).
In the brain, MAL has been shown to be necessary for the maintenance,
but not the initial formation of paranodal loops in CNS myelin. Dr. Nicole
Schaeren-Wiemers developed and characterized the MAL KO mouse. Genetic
ablation of MAL resulted in cytoplasmic inclusions within compact myelin,
paranodal loops that were everted away from the axon, and disorganized
transverse bands at the paranode-axon interface (Schaeren-Wiemers 2004).
Schaeren Wiemers et al. hypothesized that this phenotype was the result of
aberrant trafficking of oligodendrocyte membrane proteins such as neurofascin
155 and other paranodal proteins. Despite these myelin abnormalities, MAL KO
mice show no signs of disability.
Nonetheless, most of the experimental MAL data have come from
exploring MAL’s role in epithelial cell function. A variety of tissues express
MAL and expression is primarily of epithelial origin (Table 8). Absorptive cells
(e.g. enterocytes), and many different types of specialized secretory cells, either
organized in discrete clusters (e.g. endocrine cells in the pancreas), gathered
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together in an endocrine gland (e.g. thyroid), interspersed with other cells in
glands (e.g. parietal cells), or dispersed singly among other cells (e.g. type 2
pneumocytes) are positive for MAL (Marazuela, Acevedo et al. 2003).

Table 8. A Summary of the Distribution of MAL in Different Human Tissues
667

MAL in Human Epithelia

(Marazuela, Acevedo et al. 2003)
Table 1

Summary of the distribution of MAL in different human tissues

Tissue/organ

Strong expression

Weak or focal expression

Common structures

Axons
Mast cells

Skin

Ductal eccrine cells

Esophagus

Stratified squamous epithelium

Stomach

Surface mucous cells

Large intestine

Parietal cells
Chief cells
Crypt cells
Paneth cells
Lymphocytes (Peyer’s patches)
Mucous cells

Liver

Centrilobular hepatocytes

Pancreas

Acinar cells

Kidney

Distal convoluted tubules
Collecting tubules

Other hepatocytes
Intrahepatic ductal epithelium
Ductal cells
Endocrine cells
Loop of Henle

Small intestine

Ureter
Bladder
Prostate
Lymph node

Enterocytes with microvilli

Superficial cells from transitional epithelium
Ductal and acinar cells
T-cells
HEV endothelium

Tonsil

T-cells
HEV endothelium
Superficial and crypt epithelium

Thymus

Cortical thymocytes

Bronchi and trachea
Lung
Thyroid gland
Testis
Adrenal gland

Goblet cells
Type 2 pneumocytes
Leydig cells
Medullary cells
Zona reticularis

Medullary thymocytes
Hassall’s corpuscles
Respiratory epithelium
Mucous cells
Thymocytes
Sertoli cells
Zona glomerulosa
Zona fasciculata

No expression
Endothelial cells
Fibroblasts
Muscle cells
Keratinized epithelium
Keratinocytes
Hair follicles
Melanocytes
Muscle cells
Submucosa
Muscle cells
Submucosa
Muscle cells
Submucosa
Muscle cells
Submucosa
Kupffer cells
Endothelium

Glomerulus
Proximal convoluted tubules
Bowman’s capsule
Juxtaglomerular apparatus
Other epithelial cells
Muscle cells
B-cells
Sinusoidal cells
Dendritic cells
Macrophages
Other endothelia
B-cells
Sinusoidal cells
Macrophages
Dendritic cells
Epithelial cells
Dendritic cells
Alveolar lining cells
Parafollicular cells
Germinal cells

gus, the stratified squamous, non-keratinizing epithebase of the crypts, including Paneth cells, were
localizes
to the2A).
apical
membrane,
and
co-purifies
with decrease
detergent
lium wasMAL
strongly
positive (Figure
The staining
strongly
positive,
with a gradual
in staining
was more pronounced in the apical layer (Figure 2B).
intensity as the cells approached the surface (Figure
When the stratified epithelium changed to the gastric,
4A). The staining of the cells of the villi showed a
resistant
lipid rafts of classical “barrier epithelia”
e.g. kidney and stomach. In
mucus-secreting simple columnar epithelium of the
characteristic pattern of reactivity similar to that obstomach there was positive staining confined to the
served for other epithelial cells, i.e., strong supranuapical portion
of MAL
the surface
mucous cell
3A). structures
clear granular
with no staining
at the basal
MDCK
cells,
localizes
to (Figure
vesicular
ofpositivity,
the trans-Golgi
network
In addition, parietal cells, responsible for the secretion
or lateral membranes (Figure 4B). This distribution
of hydrochloric acid and intrinsic factor, were highly
corresponds to the location of the Golgi apparatus. In
immunoreactive, typically in association with punc-120the Peyer’s patches, only lymphocytes in the paracortitate cytosolic structures (Figure 3B). In the small intescal zone were stained (our unpublished results).
tine, the epithelial cells lining the crypts of Lieberkühn
Throughout the gastrointestinal tract, myenteric and
had a very distinctive reaction pattern. Cells at the
submucosal plexus were strongly positive (our unpub-

and in transport vesicles. Therefore, MAL is postulated to mainly subserve
transport functions. Experimental findings support this suggestion convincingly:
transfection of MDCK cells with antisense MAL cDNA strongly reduces the rate
of apical transport in these cells. Both velocity and efficiency in the apical raft
delivery are decreased and misrouting of apically sorted proteins to the
basolateral compartment is observed. In addition, the targeting of other apically
sorted proteins, e.g. caveolin, into lipid rafts is disturbed. Velocity and accuracy
of the apical transport is also significantly increased in epithelial A498 cells that
lack endogenous MAL after transfection with recombinant MAL. In MDCK cells,
MAL overexpression leads to increased surface expression of apical proteins and
to an apparent increase of the surface area of the apical membrane. These
experiments suggest that the amount of MAL present is a rate-limiting
component of apical transport in MDCK cells. In essence, the in vitro and in vivo
observations show that MAL is an organizer and a stabilizer of
glycosphingolipid enriched microdomains in epithelial cells, and it seems that
MAL has an important function in sorting and apical transport (Frank 2000).
Finally, Magal et al. have proposed a mechanism for how MAL facilitates
lipid raft formation and resultant protein trafficking to membrane microdomains
on the apical surface (Figure 45). Site-directed mutagenesis and bimolecular
fluorescence complementation analysis demonstrate that MAL forms oligomers
via intramembrane protein-protein binding motifs. Furthermore, Magal et al.
hypothesize that MAL’s association with raft lipids is driven, at least in part, by
positive hydrophobic mismatch between the lengths of the transmembrane
helices of MAL and surrounding membrane lipids (Magal, Yaffe et al. 2009).
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Figure 45. A Proposed Role for MAL in Lipid Raft Formation. Facilitation of
protein clustering and domain formation by positive hydrophobic mismatch
between MAL and membrane lipids. (a) Scheme demonstrating the possible
consequence of positive hydrophobic mismatch between MAL transmembrane
domains and the width of the hydrophobic core of the membrane bilayer. (b)
Spontaneous MAL oligomerization (red bars) is facilitated during transport
between thin-membrane organelles. In the apical membrane, where alleviated
mismatch promotes monomer formation, MAL participates in determining
membrane thickness. ARC, apical recycling compartment. (Magal, Yaffe et al.
2009)
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Figure 7. Facilitation of protein clustering and domain formation
by positive hydrophobic mismatch between MAL and membrane
lipids. (a) Scheme demonstrating the possible consequence of positive hydrophobic mismatch between MAL TMDs and the width of
the hydrophobic core of the membrane bilayer. (b) Spontaneous
MAL oligomerization (red bars) is facilitated during transport be123In the apical membrane, where
tween thin-membrane organelles.
alleviated mismatch promotes monomer formation, MAL participates in determining membrane thickness. ARC, apical recycling

MAL’s apical/lumenal distribution, ability to self oligomerize and high
density of aromatic residues in its second extracellular loop make it an attractive
candidate as an ETX receptor. As a barrier disruptor, ETX will likely target a
molecule that is localized to the apical/lumenal surface. Furthermore, as ETX
needs to heptamerize to form the pore complex, binding to a molecule such as
MAL that naturally exists in an oligomeric state would easily concentrate the
toxin and facilitate pore formation. Lastly, the aromatic residues of the ETX
binding domain may be able to form pi or T stacking systems of electron
delocalization with the aromatic residues in MAL’s second extracellular loop.

MAL is a bone fide ETX receptor

How the potent neurotoxin, Clostridium perfringens epsilon toxin (ETX),
targets mammalian cells remains unknown. We have identified the tetraspan
proteolipid, myelin and lymphocyte protein (MAL), as an ETX receptor.
Exogenous MAL expression renders ETX resistant CHO cells capable of ETX
binding and confers ETX susceptibility. Insertion of FLAG sequences into either
the first or second extracellular loops of MAL abolishes ETX mediated toxicity.
ETX fails to stain tissues harvested from MAL knockout mice despite robustly
staining tissues from wild type mice. Finally, MAL knockout mice exhibit
resistance to ETX doses in excess of 1000 times our experimentally determined
LD50.
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Expt 1. Is MAL sufficient to confer ETX binding and sensitivity?

RESULTS
ETX binds to and kills MAL expressing cells: We stably transfected ETX
resistant Chinese Hamster Ovary (CHO) cells with a Green Fluorescent Protein
rat MAL fusion protein construct (CHO-MAL), and found that these cells were
able to bind Alexa 594 labeled ETX, while CHO cells transfected with Green
Fluorescent Protein alone (CHO-GFP) remained unable to bind the toxin (Fig.
46A). This finding was further confirmed and quantified by assessing Alexa 647
labeled ETX binding to these two stable transfectants by Flow Cytometry. ETX
showed robust binding to CHO-MAL cells, while failing to bind to CHO-GFP
controls (Fig. 46B).
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Figure 46. MAL Is Sufficient to Confer ETX Binding. A) EGFP-MAL
transfected CHO cells (top) and GFP transfected CHO (bottom) stained with
Hoechst and ETX-594. CHO-MAL cells stain positive for ETX-594, while CHOGFP cells do not. Furthermore, ETX-594 colocalizes with the GFP signal in CHOMAL cells. B) FACS analysis of ETX-647 binding shows that CHO-MAL cells
become double positive for GFP and ETX-647 when incubated with toxin (top).
However, CHO-GFP cells remain positive for GFP only, after incubation with
ETX-647 (bottom).
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To determine if alterations to the primary structure of MAL would affect
ETX binding, we transiently transfected CHO cells with different versions of the
MAL tetraspan and incubated these cells with Alexa 647 labeled ETX. Flow
Cytometry analysis showed that ETX binds to EGFP rat MAL and EGFP human
MAL fusions, but fails to bind to EGFP human MAL with FLAG sequence
insertions in either the first or second extracellular loops. Additionally, ETX fails
to bind to the EGFP zebra fish MAL orthologue and to the GFP control (Fig. 47).
It should be noted that while ETX bound both human and rat MAL, it displayed
a ten fold increased affinity for rat MAL when compared to the human
orthologue. Although HAVCR1 has been proposed as an ETX receptor, HEK293
cells, which are HAVCR1 deficient (Bruggemann, Ivie et al. 2011), are still able to
bind ETX after rat and human MAL transfection despite lacking HAVCR1 (Fig.
48); thus HAVCR1 is not necessary for MAL mediated ETX binding.
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Figure 47. A FACS Histogram of ETX Binding to MAL. ETX-647 binds to rat
MAL (green) and to human MAL (magenta). ETX-647 fails to bind to human
MAL with a FLAG insertion in ECL1 (light blue), human MAL with a FLAG
insertion in ECL2 (orange), zebra fish MAL (dark blue) and GFP alone (red).
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Figure 48. A FACS histogram of ETX binding to MAL transfected HAVCR1
Deficient HEK293 Cells. ETX-647 binds to both rat and human MAL transfected
HAVCR1 deficient HEK 293 cells, but not to the GFP control.
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ETX is a 31 kilodalton exotoxin that binds to target membranes,
heptamerizes, generating a pore that allows the influx of ions and water, leading
to osmotic cell death (Popoff 2011). To confirm the formation of a functional ETX
pore, we assessed cell membrane permeability to propidium iodide (PI) by
fluorescence microscopy. We treated CHO-MAL and CHO-GFP cells with ETX
(500pM) and monitored PI uptake over a 24-hour period. By the 4-hour time
point, we observed robust PI uptake in the CHO-MAL, but not the CHO-GFP
controls (Fig. 49). After 24 hours, significant PI uptake remained undetectable in
the CHO-GFP controls. We further determined that ETX kills MAL transfected
cells in both a dose (Fig. 50A) and time dependent fashion (Fig. 50B) based on a
presto-blue cell viability assay (Invitrogen), which assesses the ability of cells to
reduce non-fluorescent resazurin to the fluorescent metabolite, resorufin.
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Figure 49. ETX Forms Pores in MAL Transfected Cells. Left) CHO-MAL cells
become permeable to propidium iodide 2hrs after ETX treatment (500pm). Right)
CHO-GFP cells remain resistant to ETX pore formation even after a 24-hour
incubation with ETX.
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Figure 50. MAL Transfected Cells Are Susceptible to ETX. A) CHO-MAL
exhibits ETX sensitivity in a dose dependent fashion (left), CHO-GFP fails to
exhibit ETX sensitivity at any of the administered doses (right). B) ETX kills
CHO-MAL cells in time dependent fashion, while CHO-GFP cells remain
resistant at each time point.
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Together, these data suggest that exogenous MAL expression is sufficient
to confer ETX susceptibility. As additional confirmation that MAL is truly
involved ETX toxicity, we tested the susceptibility of an endogenous MAL
expressing cell line, which has no known ETX susceptibility; the human Jurkat T
cell line (Anton, Andres-Delgado et al. 2011). Toxin treated cells lost their cellcell adhesion/clustering characteristics and displayed marked swelling after
treatment with ETX (Fig. 51), confirming their inherent ETX susceptibility.
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Figure 51. Jurkat T Cells Are Susceptible to ETX. Untreated Jurkat T cells
display the typical clustered morphology (left). ETX treated Jurkat T cells
dissociate for each other and exhibit marked swelling and osmolysis (right).
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Expt 2. Is MAL necessary for ETX binding and sensitivity?

RESULTS
MAL ablation abolishes ETX binding and toxicity: Finally, we wished to
determine if MAL is necessary for ETX binding and/or toxicity. We procured
MAL knockout (KO) mice from Dr. Nicole Schaeren-Wiemers (University
Hospital Basel, Switzerland) and harvested tissues known to express MAL, brain
and kidney (Frank 2000). We also harvested eye tissue, as we postulated that the
vessels comprising the blood-retinal barrier might also express MAL. MAL
deficient mice show no overt physical or behavioral abnormalities, however, a
defect in the maintenance of paranodal myelin loop structure has been observed
upon examination of CNS myelin by electron microscopy.
In wild type (WT) mice, Alexa 594 labeled ETX stained CNS myelin (Fig.
52), retinal microvessels (Fig. 53), squamous epithelium of the cornea (Fig. 54)
and renal tubules (Fig. 55). However, ETX failed to stain these same structures in
the MAL KO mouse. Despite this lack of staining in KO mice, control markers
for CNS white matter (PLP), retinal vessels and corneal epithelium (BSL1), and
renal tubules (Alexa 488 labeled Shiga toxin 1 beta) showed no difference in
staining for KO vs. WT mice. Of note, human T lymphocytes are known to
express MAL and we have shown that the human Jurkat T cell line is ETX
sensitive (Fig 51). However, we failed to observe ETX staining of splenic T
lymphocytes harvested from wild type mice (data not shown).
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Figure 52. MAL Is Necessary for ETX to Bind to CNS White Matter. A brain
section from a wild type mouse (top panel) stains for PLP (myelin marker) and
ETX-594. The merged image shows almost compete overlap. A brain section
from a MAL knockout mouse (bottom panel) stains for PLP, but not for ETX-594,
thus there is no colocalization in the merged image.
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Figure 53. MAL Is Necessary for ETX to Bind to Retinal Vessels. (Left) retinal
vessels from a wild type mouse stain positive for BSL (a pan vessel marker),
ETX-594 and DAPI. (Right) retinal vessels from a MAL knockout mouse stains
for BSL and DAPI, but fails to stain for ETX-594.

137

!"#$%&'()*'+&,&--.%/0'!1$2%&-,&3,&'4",%2-,25/'67'8-*'9:')2%3&.'(;<'''''''''''''''
*+,)-.)

=>?@ABCDAE7<'

!"#$%&'()

F;GH'

Figure 54. MAL Is Necessary for ETX to Bind to The Cornea. (Left) squamous
epithelium of the cornea from a wild type mouse stains positive for BSL lectin,
ETX-594 and DAPI. (Right) cornea from a MAL knockout mouse stains for BSL
lectin and DAPI, but fails to stain for ETX-594.
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Figure 55. MAL Is Necessary for ETX to Bind to Renal Tubules. (Left) a kidney
tissue section from a wild type mouse stains positive for shiga toxin-488 (green),
ETX-594 (red) and DAPI (blue). (Right) a kidney tissue section from a MAL
knockout mouse stains positive for shiga toxin-488 and DAPI, but is negative for
ETX-594 binding.
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The hallmark of ETX toxicity is cerebral edema as a result of blood-brain
barrier breakdown (Bokori-Brown, Savva et al. 2011). However, we did not
observe robust ETX staining in brain vasculature. This may be due to the fact
that ETX has a predilection for white matter vessels (Finnie 1984; Finnie 1984)

!"#$%&$'()(&&*+,$-.+$%'$/%/.$012$3.4%)%
and it may be difficult to visualize vascular staining in white matter, as the

vascular signal may be obscured by the surrounding myelin signal. The retina is
a CNS tissue that is devoid of myelin, and we observed ETX staining of bloodretinal barrier vasculature, suggesting that these microvessels express MAL.
Because ETX failed to bind tissues harvested from MAL KO mice, we
went on to compare ETX toxicity in MAL KO (n=5) versus WT (n=5) animals.
We found that MAL KO mice were completely resistant to ETX (Figure 56). We

also subjected MAL deficient mice to ETX doses that were in excess of 1000 times
our experimentally determined LD50 and found that these animals remained
unaffected even when injected with extremely high doses of toxin.
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Figure 56. MAL Is Necessary for ETX Toxicity In Vivo. (Foreground), a wild
type mouse injected with 50ng of ETX IP lays obtunded. (Background), a MAL
KO mouse injected with 50ng of ETX IP remains fully alert and unaffected.
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SUMMARY
In summary, we have shown that exogenous MAL expression confers ETX
binding and susceptibility to an ETX resistant CHO cell line. We have identified
the Jurkat T cell line, an endogenous MAL expresser, as a novel ETX sensitive
cell line, further confirming that MAL is sufficient for ETX susceptibility.
Furthermore, the inability of ETX to bind to tissues from MAL KO mice and the
high degree of ETX resistance in KO animals demonstrate that MAL is also
necessary for ETX toxicity. Finally, we have determined that both blood-retinal
barrier and blood-brain barrier endothelial cells express MAL, a finding that
supports the idea that MAL plays a role in barrier function.

MATERIALS AND METHODS

Generation of MAL constructs - pβ-actin-ECGFP-rat MAL construct was kindly
provided by Nicole Schaeren-Wiemers of University Hospital Basel, Switzerland
(Caduff, Sansano et al. 2001). Constructs for human MAL and human MAL with
FLAG sequence insertion in the 2nd extracellular loop were gift of Miguel
Alonso of Universidad Autonoma de Madrid, Spain. Human MAL and human
MAL with the FLAG insertion in 2nd loop were subcloned and inserted into Nterminally GFP expressed pβ-actin-ECGFP vector. Human MAL with a FLAG
insertion in the 1st extracellular loop was synthesized (RsrII/XbaI restriction
sites included), and purchased from Genewiz, Inc. A plasmid encoding Zebra
fish MAL was purchased from ATCC, subcloned and inserted into the pβ-actinECGFP vector. The GFP control vector for stable cell expression is pEGFP-C1
from Addgene. All recombinant plasmids were grown in One shot Top
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10 Escherichia coli (Invitrogen). Sequence analysis and verification were
performed (Macrogen USA). Plasmids were subsequently amplified and
purified (Qiagen plasmid purification kit).

Cell Culture and Transfection - Chinese hamster ovary (CHO) cells were grown
in Dulbecco's modified Eagle's Medium/Ham's F12 medium (gibco) with 10%
heat-inactivated FBS, 50 units/ml penicillin and 50 µg/ml streptomycin
(Invitrogen). CHO cells were transfected with the indicated expression plasmids
using turbofect (Fermentas) according to the manufacturer’s instructions. For
stable cells, clumps of cells were collected after growing transfected cells in the
growth medium with G418 400 µg per ml for 3 weeks. Cells were then analyzed
under fluorescent microscope for enriched GFP expression. GFP enriched cells
were FACS sorted by Becton-Dickinson Vantage cell sorter and clonally
expanded.

Cell Viability Assays:
Presto Blue assay - PrestoBlue Reagent (molecular probes, invitrogen): CHOEGFP cells and CHO-EGFP-MAL cells were grown together with ETX in 384 well
plate for overnight. 10X PrestoBlue cell viability reagent, which is quickly
reduced by metabolically active cells and highly red fluorescent, was added into
each well of plate by multi-drop liquid dispenser. Then fluorescence intensity
was measured by Microtiter plate reader Perkin-Elmer Envision.
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Propidium Iodide Uptake Assay - Cell membrane permeability was assessed by
determining the ability of cells to exclude the DNA-binding fluorescent dye
propidium iodide as previously described (McGahon, Martin et al. 1995). Cells
were grown in 6 well culture plates and treated with ETX for indicated times.
Then cells were immediately stained by propidium iodide of pSIVA™-IANBD
Apoptosis/Viability Microscopy Set (IMGENEX) and imaged under fluorescent
microscope.

Jurkat T cell culture and ETX treatment - Human T lymphoblastoid Jurkat cells
(ATCC Cat#TIB-152) were grown in RPMI 1640 supplemented with 5% FBS
(Sigma-Aldrich), 50 U/ml penicillin, and 50mg/ml streptomycin at 37˚C in an
atmosphere of 5% CO2/95% air, in T75 flasks until confluent. ETX (150nM) or
PBS vehicle control was added to each flask and incubated for 37 degrees C for 8
hours.
Fluorescent labeling of toxins - His tagged ETX prototoxin was procured from
BEI Resources. One mg was fluorescently labeled using Alexa Fluor 594 Protein
Labeling Kit (Invitrogen) and 1 mg was labeled using Alexa Fluor 647 Protein
Labeling Kit (Invitrogen) as per manufacturer's instructions. His tagged Shiga
toxin 1β was procured for BEI Resources and fluorescently labeled using Alexa
Fluor 488 Protein Labeling Kit (Invitrogen).

Flow Cytometry - Transfected cells were removed from the tissue culture
substrate by incubating with citric saline (135µM potassium chloride, 15µM
sodium citrate dissolved in sterile water) for 5 mins at 37 degrees C. Cells were
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washed of the plate and triturated well to obtain single cell suspensions. Cells
were washed 3 times with DMEM without phenol red (Invitrogen), containing
10% fetal calf serum, 50 U/ml penicillin, and 50mg/ml streptomycin. Cells were
diluted to 5x105/ml and incubated with 20nM Alex 647 labeled ETX for 1 hour at
37 degrees C. Labeled cells were washed 3 times in DMEM lacking phenol red,
and read on the AccuriC6 Flow Cytometer.
Fluorescence microscopy:
Cells - Stably transfected rat MAL (CHO-MAL) and GFP (CHO-GFP) were
plated on glass bottom dishes (Mattek) at a density of 6x104 cells/ml, and
allowed to grow overnight. Cells were subsequently washed and fixed with 4%
PFA for 10 mins at room temp. Cells were washed and incubated with Alexa 594
labeled ETX (50nM) for 1 hour at room temp. After incubation, the cells were
washed 3 times in PBS and Hoechst (1µg/ml) was added to visualize nuclei.
Stained cells were visualized by confocal microscopy at The Rockefeller
University Bio-Imaging Facility.
Brain Tissue - Fresh frozen tissue sections were fixed in 4% PFA (10 mins RT),
permeabilized in a 1% sodium cholate, 1% BSA, 10% donkey serum, PBST
solution overnight at 4 degrees C (Dorca-Arevalo, Martin-Satue et al. 2012).
Sections were then incubated with rabbit anti-PLP (ThermoScientific) at 1:1000
overnight at 4 degrees C. Following three washes with PBS, sections were then
incubated with Donkey anti-rabbit Alexa 488 (Jackson ImmunoResearch) at
1:1000, and Alexa 594 labeled His-tagged protoxin (50nM) for 2 hrs at RT. The
stained tissue was washed 3X in PBS, mounted and imaged.
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Retina/Cornea - Fresh frozen tissue sections were incubated with BSLI (Vector
Labs) 1:200, and Alexa 594 labeled His-tagged protoxin (50nM) for 1 hr at RT.
After three 5 minute washes in PBS, stained sections were post fixed in 4% PFA
for 10 mins at RT. The stained tissue was washed 3X in PBS, mounted and
imaged.
Kidney - Fresh frozen tissue sections were fixed in 4% PFA (10 mins RT), washed
and incubated with Alexa 488 labeled His-tagged Shiga toxin 1β (200nM) and
Alexa 594 labeled His-tagged protoxin (50nM) for 1hr RT. The stained tissue was
washed 3X in PBS, mounted and imaged.
ETX toxicity in mice - All animal work was conducted under the WCMC animal
protocol number 2012-0030. Each mouse was injected with ETX via
intraperitoneal injection and the time-to-death determined.

DISCUSSION
Although confident that MAL is a functional ETX receptor, we realized
one discrepancy that had to be addressed. Previous investigators have
postulated that the ETX receptor would be a glycoprotein because the
elimination of carbohydrate moieties by neuraminidase treatment (Nagahama
and Sakurai 1992) and by beta-elimination (Dorca-Arevalo, Martin-Satue et al.
2012) mitigate ETX toxicity. While MAL is not a glycoprotein, it does reside in a
glycolipid rich environment, the lipid raft. We speculated that neighboring
glycolipids may act as ETX co-receptors or may modulate the ETX/MAL
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interaction. While it has been recognized that glycosphingolipids can affect ETX
toxicity, experimental data contradicts our hypothesis. Inhibitors of sphingolipid
or glycosphingolipid synthesis increase cell susceptibility to ETX, whereas
inhibition of sphingomyelin synthesis or addition of GM1 dramatically decreases
ETX binding and subsequent heptamerization (Shimamoto, Tamai et al. 2005).
Importantly, Shimamoto et al. suggest that the GM1 inhibition is not due to
competitive inhibition by free GM1 in the culture media. They also find that
lipid raft GM3 inhibits ETX binding. Finally, the fact that C. perfringens secretes a
neuraminidase of its own that reportedly increases ETX toxicity (Li, Sayeed et al.
2011) suggests that carbohydrate moieties may inhibit ETX binding. As many
conflicting data regarding the role of carbohydrates in ETX binding/toxicity
exist, we wished to determine if glycolipids were necessary for ETX binding and
toxicity.
We procured the glycosphingolipid deficient GM-95 cell line, which lacks
the enzymes necessary for glycolipid synthesis from Dr. Deborah Brown (Stony
Brook). We also procured the MEB-4 melanoma cell line, which is the parental
cell line for the GM-95 mutant, to use as an appropriate glycosphingolipid
expressing positive control. We found that both cell lines were susceptible to
ETX toxicity after transient transfection with MAL (data not shown), thus
glycosphingolipids are not necessary for ETX/MAL binding or ETX pore
formation.
It also seems that a rigid 3 dimensional structure of the MAL extracellular
loops (ECLs) may be necessary for ETX binding. We generated short peptides of
both MAL ECLs and pre-incubated ETX with each ECL alone and with the two
loops combined, and found that no competitive inhibition occurred (data not
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shown). These data suggest that ETX may only be able to recognize MAL in a
particular conformation that is stabilized by the rigidity of the surrounding
membrane.

MAL in the context of Multiple Sclerosis: In Table 8, it is clear that many
different cell types (mostly epithelial cells) in many different tissues express
MAL. If ETX triggers MS and ETX binds to MAL, wouldn’t one observe tissue
damage in these various sites? One must realize that the cells that express MAL
typically form lumens. If ETX is being absorbed via the intestine, it will have
access to the gut lumen, the lumen of vascular system and after disrupting the
BBB, the specialized membranes of MAL expressing oligodendrocytes. Other
MAL expressing lumenal tissues, which have no contact with blood such as
stomach epithelium, thyroid epithelium and thymus epithelium will remain
unexposed to ETX during hematogenous dissemination.
Since human T lymphocytes express MAL and circulate in the blood,
would one not observe T cell abnormalities during an MS exacerbation?
Provocatively, this is exactly what has been observed. A 1981 study by Dr. Byron
Waksman (The National MS Society) found that during, or up to a week prior to
an acute MS attack, T cell abnormalities could be observed. The number of
circulating T lymphocytes dropped, and up to 20% of the T cells still in
circulation displayed an enlarged morphology (Figure 57) (Waksman 1981).

147

89

% of conA lymgo in MS
immunoin stimuted with
lympho-

Multiple
nthly by
tracts in
of MBP,
EB virus
indirect
ade more
patients'
toxicity,
A, and
ontaining

lso been
y use of
othing is
rus?). C3
CSF also

IgA, and
/albumin
are synpattern of
electrorticularly

Figure 57. Enlarged Lymphocytes During Acute MS. Lymphocytes from

Fig. 2. L y m p h o c y t e s from patients with active m u l t i p l e sclerpatients with active multiple sclerosis (A, B, C) contrasted with a lymphocyte
osis
(A, B, C) contrasted with a l y m p h o c y t e f r o m a n o r m a l
under identical
conditions
d ofrom
n o r aonormal
b t a i n edonor
d u nobtained
d e r identical
conditions
(D).(D). Blast-like cells
similar
to those
illustrated
for 20%here
of themay
whiteaccount
cells in the
Blast-like
cells
similarhere
to may
thoseaccount
illustrated
for
20°70
of the white
cells in Wrights
the circulation
of MS
patients.
circulation
of MS patients.
stain (l000X).
(Waksman
1981)
Wrights stain (xl000). From S. Armentrout and S. van der
Noort, unpublished.
Dr. Waksman described these cells as “blast-like” due to their enlarged
cytoplasm, however,of
one MS,
would not
expect T cell
to be present
the
characteristic
reflects
theblasts
pattern
of inlgG1
eluted
plaques
in enlargement
the same
circulationfrom
in cases the
other than
leukemia. themselves
We propose that this
of
patient. Since up to 30 IgG bands may be found in
the cytoplasmic space may be due to ETX exposure, pore formation and cellular
eluates from a single plaque, much of this may be
swelling, reminiscent
of what
observed
Figure 51 when
treated the
antibody
irrelevant
towasthe
MS inprocess.
It isweprobable
that
to Tbe
the circulaJurkatBT cells
cell linewhich
with ETX.happen
The fact that
cellpresent
counts alsoin
decreased
during and
tion
at a given time, whatever their specificity, are
immediately before MS exacerbations corroborates this idea of T cell cytotoxicity.
recruited by a nonspecific local stimulus during the
early evolution of the lesion and remain as resident
plasmacytes.
Multiple antivirus antibodies,
especially to measles
148
antigens, are present in CSF IgG '2. A single sample of
CSF may contain several, as well as antibodies to

Interestingly, a decrease in T cell membrane potential has also been observed
(Bauer, McFarlin et al. 1982) further supporting this notion.

Future Directions

Using T cells to probe for ETX during acute MS attacks: T cell susceptibility
may provide the perfect opportunity to identify ETX in MS patients. Because
nascent MS lesion brain specimens will be very rare and difficult to procure,
circulating T cells harvested from symptomatic MS patients may serve as an
easily accessible tissue that may be ETX positive. Indeed, we show that one can
detect the ETX pore in T cells that have been isolated from blood incubated with
ETX via a Western blot assay (Figure 58).
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Figure 58. Detection of The ETX Pore in Human T Cells. ETX forms pores in
human T cells that can be detected by Western blot. (Left) membranes from ETX
treated (150nM) rat MAL transfected CHO cells are strongly positive for the ETX
complex (approx. 145kD). (Right) T cell membranes isolated from ETX treated
(15nM) human blood are positive for the ETX complex.
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MATERIALS AND METHODS
T cell isolation - We drew two full lavender tops of human blood and spiked
one tube with ETX (15nM). The blood was incubated on a shaker at RT for 1 hr.
After an hour we added an equivalent volume of PBS 2%FBS to each sample and
mixed gently. We layered the diluted blood on the appropriate volume of ficoll
and centrifuged for 20mins, 1200g at 25C. We collected and centrifuged cells
from all layers above RBC layer at max speed for 1 min and resuspended the
cells in PBS and washed 2X. We eliminated contaminating RBCs by
resuspending the cells in RBC lysis buffer and incubating for 5 mins on a shaker
at RT. The cells were then resuspended in PBS and washed 2X.
Membrane isolation and Western blot analysis - The isolated T cells were
resuspended in transmembrane exaction buffer (starting blood volume/50) and
incubated on ice for 1hr (vortexed for 30secs every 15 mins). We added 4x
sample buffer and ran on SDS page. We then transferred to a PVDF membrane,
blocked with 2% milk for 1hr RT and incubated with rabbit anti-ETX peptide
KASYDNVDTLIEKGR (a custom antibody made by Pacific Immunology) 1:1000
at 4 C ON. The following day, we incubated with goat anti-rabbit F(ab')2
1:10,000 and developed and imaged.

While an important preliminary experiment, harvesting T cell membranes in
aggregate and screening by Western blot may not be the most sensitive
approach. If we successfully develop an aptamer that can access the ETX pore,
as discussed in Chapter 2, we may be able to use a fluorescently tagged aptamer
to probe individual T cells by FACS analysis (Figure 59). This may increase our
sensitivity for detecting ETX on the T cell membrane many fold.
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Figure 59. FACS Analysis of T Cells from Symptomatic MS Patients.
Fluorescently labeled DNA aptamers that have been generated against the ETX
pore will be used to probe MS T cells, cell by cell. (adapted from Abcam)
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Prove that a physical interaction between MAL and ETX exists: While we have
determined that MAL is both necessary and sufficient for ETX binding we have
not proved that a physical interaction between the two molecules exists. Because
the extracellular surface of a living cell is rich with a variety of molecules and
epitopes, we wish to simplify the surface with which ETX interacts to determine
if it indeed binds to MAL. This can be achieved by making artificial vesicles that
contain purified MAL and no other proteins. We have established a
collaboration with the Dr. Brian Kloss at the New York Consortium of Membrane
Protein Structure (NYCOMPS) and have begun to synthesize and purify different
versions of the MAL molecule which we will then incorporate into unilamellar
vesicles. Once incorporated into vesicles, we will utilize techniques such surface
plasmon resonance (SPR) to determine the ETX dissociation constants for each
MAL species.

Determine the species differences in ETX/MAL binding: One surprising
finding was that rat MAL displayed a 10-fold increase in ETX binding affinity
when compared to human MAL, and that zebra fish completely failed to bind
ETX (Figure 47). We hypothesize that the varying number of aromatic residues
in the second extracellular loop of MAL may account for this; rat (6), human (5),
zebra fish (3). Interestingly, MAL expressing MDCK cells, which are of canine
origin are also susceptible to ETX; canine (4). By our hypothesis, canine MAL
should bind ETX with a lower affinity that human MAL, which has 5 aromatic
residues in ECL2. When considering MAL from other species e.g. ruminant
animals, there are differences in both the order and identity of aromatic residues,
e.g. histidine may be replaced by tyrosine. We wish to clone as many different
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MAL orthologues as possible into our expression vector and determine the
relative binding affinities. Below is a sequence comparison of MAL ECL2 from
different species (Figure 60):
Sheep MAL:

TIELQDGFFYKYYHENISAVV

Rat MAL:

TITMFDGFTYRHYHENIAAVV (6)

Mouse MAL:

TISMFDGFTYKHYHENIAAVV (6)

Human MAL:

TITMQDGFTYRHYHENIAAVV(5)

Bovine MAL:

AIQLQDGFLYKYYHENISAVV (5)

Hamster MAL: TIMMYEGYTYKQYHENISAVV
Canine MAL:

(6)

(5)

TIGMQEGYTYKQYHENISAVV (4)

Zebra fish MAL: TINMKVFSAVNNYYQIDISAVV (3)
Xenopus MAL:

TIALSNVTIYQLYQENIAAVV

(2)

Figure 60. Sequence Comparison of the MAL ECL2. Aromatic residues are
colored in red and the number of aromatics in each sequence is tallied on the
right side.

Develop a small molecule ETX inhibitor: Lewis et al. have used MDCK cells in
a high throughput cell survival assay to screen for compounds that inhibit ETX
toxicity (Lewis, Weaver et al. 2010). They have identified 3 compounds, which
modestly decreased ETX toxicity (Figure 61). We wish to improve upon this
work by using our stably MAL transfected CHO cells to probe for small molecule
inhibitors. Our MAL transfected cells are approximately 1000X more sensitive to
ETX than MDCK cells, thus less toxin must be used. Using a lower concentration
of toxin in a more sensitive system may increase the sensitivity of the assay and
increase the number of candidate molecules identified.
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We have performed preliminary experiments using a LOPAC library of
1280 compounds and have identified a few compounds that seem to increase cell
survival from 0% to approx. 30% (Figure 62). We will continue by screening a
library with a much larger catalogue of compounds in hopes of identifying more

/(!0#1&123(

ETX inhibitors.

Figure 62. Candidate ETX Inhibitors from The LOPAC Library (1280
!"#$$%&%'()%(*+,-.((
compounds). Blue dots signify cells that have not been treated with ETX,
representing maximum survival. Red dots signify ETX treated cells that have not
been treated with a test compound. Gray dots signify ETX treated cells that have
also been treated with a test compound. Gray dots in green circles signify cells
that have been treated with a potential ETX inhibitor.
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CONCLUDING REMARKS

The ETX/MS Hypothesis Summarized

In summary, we propose that ETX secreted by Clostridium perfringens
type B/D, or perhaps a bacterium that has acquired the ETX gene by horizontal
gene transfer, may be sufficient to trigger MS. ETX targets the two tissues that
are affected during each MS relapse, the BBB and the myelin sheath.
Furthermore, ETX targets the retina, which is devoid of myelin and yet shows
unexplained signs of vascular damage in MS patients. We have identified a 10fold increase in anti-ETX seroreactivity in MS patients when compared to healthy
controls and have found that MS patients are less likely to carry C. perfringens
type A, a non-ETX producing competitor of toxinotypes B and D. We have
described the first human to carry C. perfringens type B and this individual has
been recently diagnosed with MS. We have identified MAL as a functional ETX
receptor and have shown that it is both necessary and sufficient for ETX binding
and toxicity. The fact that MAL is a myelin protein, and we have shown that it is
also expressed at the BRB and BBB, supports the ETX/MS theory. Below we
have illustrated and summarized a proposed disease mechanism for Multiple
Sclerosis in which C. perfringens epsilon toxin is the triggering agent:
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We reason that the environmental trigger for initial lesion formation in MS might be a soluble toxin base
on the histopathologic features of the earliest lesions and propose that C. perfringens ETX fulfills th
relevant criteria for a MS disease initiator: ETX binds to BBB endothelium, disrupts BBB function and bind
to CNS white matter!HI@)* +,,-* .--41J;#3I$%K3;%)* -0C/* .++D1L;F&#MN;O&#)* +,,C* .>-1PI'Q#$&F)* +,,
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Figure 1. A proposed pathophysiologic mechanism for MS incorporating ETX as a disease initiator.

Figure 63. A Schematic of the ETX/MS Hypothesis

1. Clostridium perfringens exists in the environment (e.g. soil, marine sediment,
food). C. perfringens type A outcompetes types B and D making them less
prevalent in certain environs. Endospores are exceedingly stable in the
environment and in animals. Thus once the organism enters an environmental
niche it is likely there “forever”.
2. Susceptible individuals become colonized by C. perfringens type B or D
sometime during life. Colonization may be determined by host factors, including
host genetics, the composition of resident microbiota and microbial exposure.
Since C. perfringens type A, which does not carry ETX, competes with other
toxinotypes for space within a niche, we predict that C. perfringens type A will be
less prevalent in the MS population.
3. In colonized individuals, C. perfringens type B or D resides in low abundance
within the upper gastro-intestinal (GI) tract, rendering detection difficult since
endospores are highly resistant to degradation techniques used to isolate
RNA/DNA. An environmental change, perhaps diet, free carbohydrate load or a
currently unknown factor triggers a growth phase in C. perfringens type B or D.
With log-phase growth comes commensurate transcription of the ETX gene,
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translation and secretion of ETX. Unlike ruminant animals, humans (and
rodents) do not support substantial C. perfringens type B or D bacterial loads,
thus the amount of growth as well as toxin production is relatively small. This
may explain why humans and rodents do not suffer as severe a disease course as
ruminants.
4. Relatively small amounts of toxin enter the bloodstream through the small
intestine. The small intestine epithelium has ETX binding sites, leading to subtle
intestinal injury, barrier permeabilization, and leak of toxin from the intestine
into the blood. Seroconversion to ETX antibody positive status happens in a
fraction of patients and may be short lived due to the small quantity of toxin
antigen, and the difficulties that mammals have maintaining humoral immunity
against ETX.
5. Toxin binds to endothelial cells in the CNS leading to disruption of BBB
function, a characteristic feature of the earliest MS lesions. Remarkably, prior
studies in rodents show that ETX exposure results in ovoid lesions characteristic
of MS Dawson’s fingers.
6. Where the BBB has been disrupted, ETX enters the parenchyma and binds to
oligodendrocytes, forms pores and leads to oligodendrocyte death in the absence
of an inflammatory infiltrate, a characteristic feature of the earliest MS lesions.
7. Following the formation of the initial lesion, tissue injury leads to antigen
presentation, epitope spreading and adaptive immune responses that can
propagate damage to CNS.

158

Caveats to the ETX/MS Hypothesis

While a provocative hypothesis for initial lesion formation in MS, there
are inconsistencies in the ETX/MS hypothesis that must be considered. 1) ETX
reproducibly causes symmetrical brain lesions in affected animals, while MS
lesions can be, but are not always symmetrical. 2) ETX enterotoxaemia is often
lethal in ruminant animals, while MS exacerbations rarely result in death. 3)
Natalizumab (Tysabri), an effective MS treatment, prevents the entry of immune
cells into the CNS. Therefore, it is clear that the immune system plays an
essential role in MS pathophysiology. In summary, while ETX offers mechanistic
plausibility for early lesion formation, questions remain regarding its alleged role
in Multiple Sclerosis.
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